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Abstract 
The 21st century brought about a dramatic increase in knowledge about genetic 
and molecular profiles of cancer.  This information has validated the complexity of tumor 
cells and increased awareness of “nodal proteins”, but has yet to advance the 
development of rational targeted cancer therapeutics.  Nodal proteins are critical cellular 
proteins that collect biological inputs and distribute the information across diverse 
biological processes.  Survivin acts as a nodal protein by interfacing the multiple signals 
involved in mitosis and apoptosis and functionally integrate proliferation, cell death, and 
cellular homeostasis.  By characterizing survivin as a target of both Type 1 Insulin-like 
Growth Factor (IGF-1) and Notch developmental signaling, we contribute to the 
paradigm of survivin as a nodal protein.  The two signaling systems, Notch and IGF-1, 
regulate survivin by two independent mechanisms.  Notch activation induces survivin 
transcription preferentially in basal breast cancer, a breast cancer subtype with poor 
prognosis and lack of molecular therapies.  Activated Notch binds the transcription factor 
RBP-Jκ and drives transcription from the survivin promoter.  Notch mediated survivin 
expression increases cell cycle kinetics promoting tumor proliferation.  Inhibition of 
Notch in a breast xenograft model reduced tumor growth and systemic metastasis.  On 
the other hand, IGF-1 signaling drives survivin protein translation in prostate cancer cells.  
Binding of IGF-1 to its receptor activates downstream kinases, mammalian target of 
rapamycin (mTOR) and p70 S6 protein kinase (p70S6K), which modulates survivin 
mRNA translation to increase the apoptotic threshold.  The multiple roles of survivin in 
tumorigenesis implicate survivin as a rational target for the “next generation” of cancer 
therapeutics. 
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Chapter 1. Introduction  
The discovery of microarray technology, RNA silencing, and genomic sequencing 
provided a vast database of information about cancer, cancer genes, and cancer pathways 
(Vogelstein and Kinzler 2004; Lu, Getz et al. 2005; Bild, Yao et al. 2006; Wood, Parsons 
et al. 2007).  Thus far, the information has not affected cancer patients who suffer from 
stagnant survival rates over the last thirty years (Ries, Melbert et al. 2008).  Dozens of 
“targeted” therapies enter clinical trials, some like imatinib (Kohn, Bauer et al. 1999), 
tamoxifen (CRC 1992), trastuzumab (Baselga 2001) have indisputable benefits, but in 
practice few targeted therapies pass phase I or II clinical trials.  Given the complexity of 
most tumors, “targeted” therapies may selectively disable one or two tumor pathways, but 
allow or even encourage tumor survival by activating alternate survival pathways (Kitano 
2004).  Even so, analysis of biological systems reveals that cancer networks rely on a 
handful of key molecules to regulate apoptosis, control proliferation, respond to growth 
inhibitory signals, and metastasize (Kitano 2004).  Disabling these key molecules, or 
nodal proteins, destroys so many essential pathways that the cancer implodes from 
cellular stress.  Survivin, an inhibitor of apoptosis protein (IAP), functions as one such 
protein.  As expected from a nodal protein, survivin is a crucial molecule in cell death 
and cell division that affects numerous cellular processes like apoptosis, proliferation, 
differentiation, and metastasis.  We identify Notch-1 and IGF-1 as two independent 
pathways that control survivin expression to drive tumorigenesis.  The work reinforces 
the concept of survivin as a nodal protein.  Selective targeting of these pathways may 
disable a key molecule required for tumor growth and survival.   
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Survivin in tumorigenesis 
In an analysis of the human cancer transcriptome, survivin surfaced as the fifth 
highest transcript preferentially expressed in cancer cells (Velculescu, Madden et al. 
1999).  Survivin, an onco-fetal protein, is expressed during embryonic development but 
not in most normal adult tissue, and dramatically re-expressed in virtually all human 
tumors (Ambrosini, Adida et al. 1997).  Furthermore, survivin is associated with stem 
cell gene signatures of mesenchymal (Taubert, Wurl et al. 2007), neuronal (Pennartz, 
Belvindrah et al. 2004), and skin (Marconi, Dallaglio et al. 2006) progenitor cells.  
Survivin homozygous knockout mice prematurely die at embryonic day 3.5 with defects 
of cell proliferation, spindle formation, and apoptosis (Uren, Wong et al. 2000; Conway, 
Pollefeyt et al. 2002) demonstrating the requirement of survivin during development.  
Knockdown of survivin results in dual phenotypes of mitotic defects, i.e. centrosomal 
abberations, multipolar spindles, and chromatin missegregation, and apoptosis, i.e. loss of 
mitochondrial membrane potential, caspase activation (Beltrami, Plescia et al. 2004).  
These characteristics may explain why overexpression of survivin in tumors is associated 
with poor prognosis, resistance to chemotherapy, and reduced patient survival (Fukuda 
and Pelus 2006).  The role of survivin in elevating the apoptotic threshold while 
preserving genomic integrity is an essential feature of tumor development.   
Survivin in Cell Division 
Survivin is required for cell division.  The functions of survivin in cell division 
fall into three main categories: participation in chromosomal passenger protein biology, 
participation in the spindle checkpoint, and regulation of microtubule dynamics.   
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Survivin is a chromosomal passenger protein (Adams, Earnshaw 2001) of which 
Aurora B (AURKB), inner centromere protein (INCENP), and borealin (CDCA8) are 
members.  Chromosomal passenger proteins are conserved proteins that migrate to the 
inner centromeres at prometaphase and metaphase, subsequently to the spindle midzone 
at anaphase and finally to the midbody and cleavage furrow in telophase (Ruchaud, 
Carmena et al. 2007). The complex is required for correction of spindle attachment 
errors, organization of a bipolar spindle, and completion of cytokinesis (Ruchaud, 
Carmena et al. 2007).  Survivin mislocalization disrupts the entire chromosomal 
passenger complex (CPC) since the localization and function of the CPC is highly 
interdependent on the recruitment of all subunits (Vagnarelli and Earnshaw 2004).  
Aurora B, a Ser/Thr kinase responsible for phosphorylation of key mitotic proteins, is the 
enzymatic component of this complex.  Survivin serves as binding partner (Honda, 
Korner et al. 2003), a substrate (Wheatley, Henzing et al. 2004) and a regulator (Bolton, 
Lan et al. 2002; Chen, Jin et al. 2003) of this kinase.   
The spindle checkpoint prevents anaphase onset by sensing the correct attachment 
of sister chromatids to the mitotic spindle.  The sensor mechanism relies on inhibition of 
the anaphase promoting complex/cyclosome (APC/C) via recruitment of BubR1 to sense 
tension across the kinetochores, and Mad2 to sense microtubule attachments to the 
kinetochores.  The spindle checkpoint can be activated in the absence of survivin, 
however, the localization of BubR1 and Mad2 to prometaphase kinetochores is impaired 
(Carvalho, Carmena et al. 2003; Lens, Wolthuis et al. 2003).  In particular, survivin is 
crucial for a stable association of BubR1 to the kinetochore to maintain checkpoint 
activation in response to lack of tension (Carvalho, Carmena et al. 2003; Lens, Wolthuis 
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et al. 2003).  As suggested by the interdependency of CPC localization, Aurora B 
depletion also impairs the spindle checkpoint (Hauf, Cole et al. 2003).  The regulatory 
contribution of survivin to Aurora B serves as a secondary component of survivin in 
spindle checkpoint biology.  
Finally, survivin has a role in microtubule dynamics.  A population of survivin 
associates with polymerized microtubules (Li, Ambrosini et al. 1998; Beltrami, Plescia et 
al. 2004).  Depletion of survivin destabilizes microtubules by increasing the rate of 
microtubule nucleation and catastrophe at multiple phases of the cell cycle, independently 
of Aurora B (Rosa, Canovas et al. 2006).  Conversely, exogenous survivin hyper-
stabilizes microtubules by reducing microtubule dynamics (Rosa, Canovas et al. 2006).  
At mitosis, survivin regulates both the number and stability of centrosomal microtubules 
(Rosa, Canovas et al. 2006) as well as the formation of kinetochore associated 
microtubules albeit most likely in distinct signaling pathways (Tulu, Fagerstrom et al. 
2006).  The regulation of microtubule dynamics by survivin also interfaces with the role 
of survivin in cell death.  Phosphorylation of microtubule associated survivin on Thr34 
by cyclin dependent kinase 1 (CDK1) protects cells from spindle poisons during mitosis 
(O'Connor, Grossman et al. 2000).  A phosphorylation deficient survivin mutant (T34A) 
acts as a dominant negative isoform that prevents association of survivin with the mitotic 
spindle and induces mitotic cell death (O'Connor, Grossman et al. 2000).   
Survivin in Cell Death 
Survivin also plays a major role in regulating cell death.  Survivin cooperatively 
interacts with adaptor or cofactor molecules as well as several members in the apoptotic 
5 
pathway to prevent cell death.  Multiple pathways converge to regulate survivin 
expression contributing to the increased threshold to apoptotic stimulation.  
Survivin is the smallest protein in the IAP family containing only one conserved 
baculoviral IAP repeat (BIR) domain, and lacking a commonly conserved RING finger 
domain at the carboxyl terminus (Ambrosini, Adida et al. 1997).  The BIR domain serves 
as binding sites for important apoptotic regulators.  Survivin, like most other IAPs, does 
not directly inhibit caspases nor exert its cytoprotection without intermolecular 
cooperation (Eckelman, Salvesen et al. 2006).  Pools of survivin in the mitochondria 
associate with Smac, a pro-apoptotic inhibitor of IAPs (Sun, Nettesheim et al. 2005).  In 
the cytosol, survivin interacts with Smac, possibly sequestering Smac and preventing the 
association with other IAPs (Song, Yao et al. 2003).  Survivin associates with hepatitis B-
X-interacting protein (HBXIP) forming a complex that inhibits caspase 9 and 
mitochondrial apoptosis, while survivin or HBXIP alone does not inhibit caspases 
(Marusawa, Matsuzawa et al. 2003).  In a similar system, survivin interacts with X-linked 
inhibitor of apoptosis protein (XIAP), the sole IAP member that directly inhibits caspases 
(Eckelman, Salvesen et al. 2006), preventing ubiquitin mediated degradation of XIAP 
(Dohi, Beltrami et al. 2004).   
The survivin-XIAP complex is also regulated in a mechanism dependent on 
compartmentalized phosphorylation of survivin (Dohi, Xia et al. 2007).  Cyclic AMP-
dependent protein kinase A (PKA) phosphorylates survivin on Ser20 in the cytosol but 
not the mitochondria (Dohi, Xia et al. 2007).  Survivin phosphorylated on this residue 
loses its affinity for XIAP and the ability to protect cells from apoptotic stimuli (Dohi, 
Xia et al. 2007).  Mitochondrial survivin is protected from the activity of PKA and 
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maintained in a dephosphorylated state by protein phosphatase 2A (PP2A) (Dohi, Xia et 
al. 2007).  This pool of survivin preserves a high affinity for XIAP, prevents XIAP 
degradation and promotes tumor growth (Dohi, Beltrami et al. 2004; Dohi, Xia et al. 
2007).  In tumors, accumulation of survivin in the mitochondria serves as a mechanism to 
concentrate a key anti-apoptosis factor in an active, functional state (Dohi, Xia et al. 
2007).   
Survivin regulation is a point of convergence for pathways contributing to cellular 
homeostasis.  Molecular chaperones in the heat shock protein (Hsp) family are 
responsible for protein folding, preventing protein aggregation, and managing the 
response to cellular stressors (Sreedhar and Csermely 2004).  Hsp90, a molecular 
chaperone used by tumor cells to promote growth and survival, associates with survivin 
protecting the molecule from degradation (Beltrami, Plescia et al. 2004).  Targeting the 
survivin-Hsp90 complex with antibodies or a Hsp90 inhibitor reduces survivin levels and 
mimics a survivin siRNA phenotype of cell cycle arrest and apoptosis (Beltrami, Plescia 
et al. 2004).  The aryl hydrocarbon receptor interacting protein (AIP) is another 
component of the Hsp90 chaperone system that interacts with survivin to prevent 
proteasomal degradation of survivin (Kang and Altieri 2006).  Knockdown of Hsp60, a 
chaperone responsible for transporting and refolding proteins into the mitochondria,  
depletes survivin in the mitochondria and induces mitochondrial membrane 
depolarization (Ghosh, Dohi et al. 2008).  The mitochondrial chaperone network may 
protect mitochondrial survivin pools from degradation so it may exert its anti-apoptotic 
effect (Dohi, Xia et al. 2007; Kang, Plescia et al. 2007; Ghosh, Dohi et al. 2008).   
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In addition to regulation by molecular chaperones, survivin is regulated 
extensively by transcriptional elements in its promoter.  The survivin promoter is a 
TATA-less promoter containing several Sp1 sites, a CpG island, three cell cycle 
dependent regions (CDE) and one cell cycle homology region (CHR) that control 
survivin expression throughout the cell cycle (Li and Altieri 1999).  In cancer, the cell 
cycle periodicity of survivin expression is lost mainly by upregulation of survivin 
transcription.  Several cancer survival pathways promote survivin gene transcription.  The 
survivin promoter contains four putative NF-κB  binding sites that can be activated by 
human T-cell leukemia virus to drive survivin transcription (Kawakami, Tomita et al. 
2005).  In colon cancer, the developmental Wnt/TCF-4/β-catenin cascade drives survivin 
expression protecting cells from UV induced apoptosis (Kim, Plescia et al. 2003).  Other 
pro-survival cascades including the signal transduction and activator of transcription 3 
(STAT3) cytokine driven transcription factor (Kanda, Seno et al. 2004), and the E2F 
transcription activators (Jiang, Saavedra et al. 2004) induce survivin expression.  
Conversely, tumor suppressor genes including APC (Zhang, Otevrel et al. 2001), p53 
(Hoffman, Biade et al. 2002), and PML-4 (Xu, Zhao et al. 2004) negatively regulate the 
survivin promoter.  
The diverse regulatory components of survivin and its central role in inhibiting 
cell death and ensuring genomic integrity suggests that multiple signals work collectively 
to modulate survivin.  The goal of this work is to identify new networks where survivin 
may play a role.  We looked at the developmental Notch pathway and the growth factor 
IGF-1 pathway.   
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Notch signaling 
Notch signaling is a conserved developmental pathway used for cell to cell 
communication.  Conventionally, the Notch signaling system controls the fate of stem 
cells as they progress along the differentiation process (Bray 2006).  The Notch family 
consists of four Notch proteins (1-4) that differ in the number of EGF-like repeats, and 
presence of a trans-activation domain.  Mammals have five classic Notch ligands, Delta-
like-1,-3, -4 and Jagged-1, -2 that differ in the number of EGF-like repeats and the 
presence of a cysteine rich domain.  Members of the Contactin family can also serve as a 
Notch ligand in oligodendrocytes (Hu, Ang et al. 2003; Cui, Hu et al. 2004) alluding to 
the possibility of aberrant Notch activation by non-classical ligands given a complex 
tumor microenvironment.  Affinity and specificity between Notch ligands and Notch 
receptors is controlled via glycosylation of extracellular Notch (Fortini 2000; Moloney, 
Panin et al. 2000).  Once the Notch receptor is engaged, two sequential cleavages ensue: 
an extracellular cleavage by an ADAM metalloprotease and an intracellular cleavage by 
γ-secretase.  The γ-secretase cleavage releases Notch intracellular domain (NIC) into the 
cytosol.  Upon nuclear translocation, NIC binds the transcriptional repressor RBP-Jκ, also 
known as CBP-1 and CSL, in a complex involving Mastermind (MAML) and p300 
(Mumm and Kopan 2000).  NIC binding converts RBP-Jκ from a transcriptional 
repressor to an activator, subsequently initiating transcription of a myriad of genes, most 
prominently the Hes family of transcription repressors (Table 1-1) (Imatani and Callahan 
2000; Grabher, von Boehmer et al. 2006).  Other NIC targets include ErbB2 (Haruki, 
Kawaguchi et al. 2005), NF-κB (Oswald, Liptay et al. 1998), c-myc (Sharma, Calvo et al. 
2006; Weng, Millholland et al. 2006), and Slug (Timmerman, Grego-Bessa et al. 2004; 
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Leong, Niessen et al. 2007).  Bcl-2 upregulation is attributed to a secondary pathway of 
Notch mediated RBP-Jκ independent signaling (MacKenzie, Duriez et al. 2004).  The 
identity of Notch targets are still under active investigation since there are often tissue 
specific transcriptional targets.   
The Notch signaling network often displays tissue specific effects.  In skin, Notch 
signaling promotes cell cycle arrest (Rangarajan, Talora et al. 2001) while in other tissues 
Notch signaling increases cell cycle progression (Radtke and Raj 2003).  A possible 
explanation is that in different tissues, Notch signals interact with different sets of 
transcription factors that control the transcripts sensitive to Notch regulation.  NIC 
classically associates with RBP-Jκ, however, in certain tissues NIC may bind other co-
activators such as Lef-1 to initiate downstream transcription (Ross and Kadesch 2001; 
Spaulding, Reschly et al. 2007).  In another setting, collaborative signaling of Notch with 
other signaling cascades directly modulates cellular responses.  Wnt co-activation with 
Notch is required for transformation of human mammary epithelial cells while Notch 
activation alone is insufficient to drive the process (Ayyanan, Civenni et al. 2006).  This 
suggests that the signaling environment affects Notch function.  For example, Notch 
signaling in various epithelial cells collaborates with TGF-β to promote cell cycle arrest 
(Niimi, Pardali et al. 2007).  In contrast, Notch signaling  in breast (Reedijk, Odorcic et 
al. 2005), T-cell acute lymphoblastic leukemia (ALL) (Weng, Ferrando et al. 2004), and 
pancreatic (Miyamoto, Maitra et al. 2003) cancer is correlated to proliferation, cell 
survival, and sometimes metastasis.   
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Mechanisms of Notch mediated tumorigenesis  
The Notch signaling network is essential for stem cell maintenance in breast 
(Buono, Robinson et al. 2006), pancreas (Murtaugh, Stanger et al. 2003), intestine (Fre, 
Huyghe et al. 2005; Stanger, Datar et al. 2005), skin (Moriyama, Osawa et al. 2006; 
Schouwey, Delmas et al. 2006), and muscle (Conboy and Rando 2002).  The same stem 
cell pathway may be commandeered for tumorigenesis.  Activating mutations in Notch-1 
is directly associated with pediatric and adult T-cell ALL (Weng, Ferrando et al. 2004; 
Mansour, Linch et al. 2006).   
In breast cancer, Notch is of emerging importance.  While many mouse models 
identify Notch deregulation as tumorigenic (Gallahan and Callahan 1987; Gallahan, 
Jhappan et al. 1996), the case in humans is only beginning to be unveiled.  In an analysis 
of 11 human breast cancers and 11 human colon cancers, Notch-1 is found to be a 
mutational hotspot only in breast cancers (Wood, Parsons et al. 2007).  In microarray 
studies, Notch-1 mRNA levels are associated with poorly differentiated tumors and lower 
chances of survival (van de Vijver, He et al. 2002).  In addition, Notch-3 seems to have a 
role in proliferative control in HER-2 negative cell lines (Yamaguchi, Oyama et al. 2008) 
however, the specific downstream players are unknown.   
Functionally, Notch most likely drives tumorigenesis via its many transcriptional 
targets which span numerous biological processes.  Induction of NF-κB (Oswald, Liptay 
et al. 1998) and Bcl-2 (MacKenzie, Duriez et al. 2004) suggests a predisposition toward 
cellular survival upon Notch activation.  Normal mammary epithelial cells stably 
transfected with NIC and RBP-Jκ resist drug-induced apoptosis by suppressing p53 
apoptotic signals (Stylianou, Clarke et al. 2006).  Notch activation in SW480 human 
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colon adenocarcinoma cells confers resistance to adriamycin, cisplatin, etoposide and 
taxol in a phosphatidylinositol 3-kinase (PI3K) dependent manner (Mungamuri, Yang et 
al. 2006).  Notch activation may affect proliferation by modulating G1/S transition via 
direct transcriptional induction of cyclin D1 (Ronchini and Capobianco 2001) or 
controlling proteasomal degradation of p27Kip1 (Sarmento, Huang et al. 2005).  In 
metastasis, Notch activation induces Slug which in turn represses E-cadherin expression 
to mediate a epithelial to mesenchymal transition (Timmerman, Grego-Bessa et al. 2004; 
Leong, Niessen et al. 2007).   
The functional parameters of Notch are very diverse.  Therefore it is likely that 
this network may enlist nodal proteins such as survivin to exert its effects.  Survivin, like 
Notch, correlates with stem cell signatures (Pennartz, Belvindrah et al. 2004; Marconi, 
Dallaglio et al. 2006; Taubert, Wurl et al. 2007), and regulates common pathways in cell 
cycle and cell death.  Furthermore, survivin is largely transcriptionally regulated in 
cancer progression.  Therefore, survivin may be controlled by transcriptional pathways 
such as Notch.   
IGF-1 signaling 
Binding of the Type 1 Insulin-like Growth Factor (IGF-1) to its cognate tyrosine 
kinase receptor Type 1 Insulin-like Growth Factor Receptor (IGF-1R) induces a 
conformational change in the receptor and activation of intrinsic tyrosine kinase activity 
that stimulates a mitogenic signaling cascade.  The phosphorylated receptor transmits 
intracellular signals through protein substrates including the growth factor receptor bound 
protein (GRB) family, the SHC protein family, the insulin receptor substrate (IRS) 
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family, and the p85 regulatory subunit of PI3K.  The receptor substrates triggers multiple 
independent signaling cascades including the PI3K/Akt pathway, the extracellular signal 
regulated protein kinase (ERK) pathway, and the mitogen activated protein kinase 
(MAPK) pathway (Craparo, O'Neill et al. 1995; Ryan and Goss 2008).  PI3K/Akt 
signaling regulates many cellular processes including cell cycle regulation, apoptosis, cell 
growth, and protein synthesis.  
Downstream of PI3K/Akt is the mammalian target of rapamycin (mTOR).  The 
mTOR protein kinase is comprised of two distinct protein complexes each with different 
targets.  The rapamycin sensitive mTOR complex 1 (mTORC1) contains raptor and 
responds to nutrient status, amino acid availability, oxidative stress, and growth factor 
stimulation by controlling protein synthesis, autophagy, and ribosome biogenesis (Hay 
and Sonenberg 2004).  Activation of mTORC1 affects protein synthesis by 
phosphorylation of p70 S6 kinase (p70S6K) and eukaryotic initiation factor 4E binding 
protein (4E-BP1) (Hay and Sonenberg 2004).  Phosphorylation of p70S6K by mTORC1 
stimulates protein synthesis by activation of S6 ribosomal protein (Ruvinsky and 
Meyuhas 2006).  The S6 ribosomal protein in association with the 18S ribosomal RNA 
forms the 40S ribosomal subunit required for translational initiation (Holland, Sonenberg 
et al. 2004).  mTORC1 phosphorylation of 4E-BP1 prevents the inhibitory association of 
the protein with eukaryotic initiation factor 4E (eIF4E).  Non-complexed eIF4E binds to 
5’capped mRNA and recruits the mRNA to the ribosomal initiation complex (Pause, 
Belsham et al. 1994).  The mTORC complex 2 (mTORC2) is less sensitive to rapamycin 
(Sarbassov, Ali et al. 2006) and contains rictor.  This complex responds to insulin, growth 
factors, serum, and nutrient availability (Frias, Thoreen et al. 2006) to regulate the actin 
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cytoskeleton (Sarbassov, Ali et al. 2004) and the Akt feedback loop (Sarbassov, Guertin 
et al. 2005).  As a regulator of protein synthesis, mTOR modulates cell size, cell 
proliferation and cell survival, all of which are key components of tumorigenesis.   
IGF-1/Akt/mTOR in tumorigenesis  
In large prospective studies of breast, colon, prostate and lung cancer, elevated 
serum IGF-1 levels have been correlated to a higher cancer risk (Ryan and Goss 2008).  
In prostate cancer, persistent IGF-1 signaling contributes to development of androgen 
independence by allowing cells to survive despite minimal androgen stimulation (Djavan, 
Waldert et al. 2001; Nickerson, Chang et al. 2001).  Constitutive activation of IGF-1R 
confers anchorage independent growth (Kaleko, Rutter et al. 1990), and conversely, 
disruption of IGF-1R reduces spontaneous transformation of mouse embryonic 
fibroblasts (Sell, Rubini et al. 1993; Sell, Dumenil et al. 1994).  Further downstream, Akt 
oncogenic signaling is a common driver of tumor formation and progression.  Somatic 
alterations in the phosphatase and tensin homolog tumor suppressor gene (PTEN), 
occurring in 30-60% of human prostate cancer, potently activate the Akt/mTOR pathway 
(Gray, Phillips et al. 1995; Komiya, Suzuki et al. 1996).  Elevation in survivin expression 
is correlated to PI3K/Akt/mTOR signaling, but the mechanisms remained unknown (Dan, 
Jiang et al. 2004).  Based on this, the IGF-1/Akt/mTOR signaling cascade was explored 
for a mechanistic relationship between survivin and IGF-1 in prostate cancer.   
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Concluding Remarks 
The validation of survivin as a nodal protein requires characterizing the roles of 
survivin in multiple networks.  An Ingenuity Analysis of survivin displays the many 
signaling molecules that interact with survivin (Figure 1-1)(Altieri 2008).  The survivin 
network rests in a cancer focused landscape with the majority of survivin interactors, 
regulators, and effectors being components of tumor development.  The goal of this work 
is to identify and characterize the role of survivin in tumorigenic signaling cascades.  As 
such, we have identified independent roles of Notch-1 and IGF-1 in regulation of 
survivin.  The Notch-1 transcriptionally driven signaling pathway may use nodal proteins 
like survivin to execute its pleiotropic effects.  We found Notch-1 transcriptionally 
targets the survivin promoter specifically in basal breast cancer, a clinical aggressive 
form of breast cancers.  In contrast, the IGF-1 pathway regulates a novel translational 
mode of survivin expression in prostate cancer.  The two pathways solidify survivin as a 
nodal protein.  Targeting survivin or its key regulatory pathways may bypass issues of 
tumor heterogeneity and allow for selective killing of cancer cells.   
15 
 
Table 1-1.  Notch mediated RBP-Jκ dependent and independent genes 
 
 
RBP-Jκ Dependent Genes 
Hes family 
transcription 
factors 
Murine Notch-1 activates transcription of 
Hes-1, a transcriptional repressor, through 
RBP-Jκ binding sites 
Cell type specific HERP1 and HERP2 
activation by Notch-1 
(Jarriault, Brou et al. 
1995; Reya, Morrison 
et al. 2001) 
ErbB2 RBP-Jκ mediate ErbB2 transcription augmented by Notch-1 
(Haruki, Kawaguchi et 
al. 2005) 
Pre T cell 
receptor  α 
(pTα) 
RBP-Jκ binds pTα enhancer element 
regulating specification of T cell lineage 
(Reizis and Leder 
2002) 
Notch 
regulated 
ankryin repeat 
protein 
(NRARP) 
NARP transcription via RBP-Jκ 
participates in inhibitory feedback look on 
Notch-1 signaling 
(Krebs, Deftos et al. 
2001; Yun and Bevan 
2003; Pirot, van 
Grunsven et al. 2004) 
Cyclin D1 
NICD induction of cyclin D1 via RBP-Jκ 
correlate with transforming ability and S 
phase progression 
(Ronchini and 
Capobianco 2001) 
S-phase kinase 
associated 
protein 2 
(SKP2) 
Notch/ RBP-Jκ transcriptional activation 
of SKP2 downregulates p21Cip1 and 
p27Kip1 to modulate cell cycle progression 
(Sarmento, Huang et al. 
2005) 
NF-κB 
Notch-1 activation overcomes RBP-Jκ 
repression by NF-κB transcription via 
RBP-Jκ binding site 
(Oswald, Liptay et al. 
1998) 
Myc NIC targets c-myc in T-cell ALL models in mouse and man 
(Sharma, Calvo et al. 
2006; Weng, 
Millholland et al. 2006) 
Slug 
Jagged-1 mediates Notch targeting of Slug 
to drive EMT in breast epithelial cells, and 
cardiac endothelial cells 
(Timmerman, Grego-
Bessa et al. 2004; 
Leong, Niessen et al. 
2007) 
RBP-Jκ Independent Genes 
Bcl-2 Notch-1 and Notch-4 induce Bcl-2 independently of RBP-Jκ 
(Deftos, He et al. 1998; 
MacKenzie, Duriez et 
al. 2004) 
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Figure 1-1.  Survivin regulatory networks complied via Ingenuity Analysis.     
Highlighted molecules are genes known to contribute to tumorigenesis.  (Altieri 2008) 
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Chapter 2. Notch survivin gene signature in basal-like breast 
cancer 
Connie W. Lee, Karl Simin, Qin Liu, Minakshi Guha,  
Chung-Cheng Hsieh, and Dario C. Altieri 
This chapter represents work contributed by the listed authors.  The text is a 
version of the manuscript submitted to Clinical Cancer Research on May 19, 2008 and is 
currently under review.  Karl Simin, Dario Altieri, and I conceived and designed the 
study.  Karl Simin and I collected and assembled the data.  Karl Simin carried out the 
hierarchal clustering of Notch-1 on the 232 breast cancer samples from the University of 
North Carolina database.  I carried out the immunohistochemical staining, assembly of 
the microarray datasets, descriptive statistical analysis for the cohorts, and the in vitro 
experiments.  Minakshi Guha kindly constructed and shared the MDA-MB-231 stable 
cell line expressing GFP under the control of the 830 nt mouse survivin promoter.  Qin 
Liu and Chung-Cheng Hsieh carried out the Pearson’s correlation coefficient statistical 
analysis based on a random effects model for meta-analysis.  All of us were involved in 
data analysis, interpretation, writing, and final approval of the manuscript.    
Abstract 
Basal-type, or “triple negative” breast cancer (lacking estrogen receptor, 
progesterone receptor, and HER-2 expression) is a high-risk disease for which no 
molecular therapies are currently available.  We studied genetic signatures in basal breast 
cancer, potentially suitable for therapeutic intervention.  We analyzed protein expression 
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by immunohistochemistry.  A hierarchical clustering analysis was carried out on a 
microarray database of 232 breast cancer patients.  Fifteen published datasets containing 
estrogen receptor (ER)-negative or -positive samples were subjected to meta-analysis for 
co-segregated gene expression.  Experiments of plasmid transfection, gene silencing, and 
γ-secretase inhibition were carried out in ER-negative MDA-MB-231 model breast 
cancer cells.  The developmental signaling regulator, Notch-1 was highly expressed in 
breast cancer, compared to normal tissue, and segregated with basal disease.  Higher 
Notch-1 levels correlated with progressively abbreviated overall survival, and with 
increased expression of survivin, a tumor-associated cell death and mitotic regulator 
implicated in stem cell viability.  Analysis of Pearson’s correlation coefficient indicated 
that Notch-1 and survivin co-segregated in basal breast cancer.  Notch-1 stimulation of 
MDA-MB-231 cells increased survivin expression, whereas targeting Notch by small 
interfering RNA (siRNA) or inhibition of γ-secretase activity suppressed survivin 
promoter activity, and reduced survivin protein levels.  A Notch-1/survivin dual gene 
functional signature is a hallmark of basal breast cancer, and may contribute to disease 
pathogenesis.  Antagonists of Notch and survivin currently in the clinic may be tested as 
novel molecular therapy of these recurrence-prone patients. 
Introduction 
The introduction of molecular “gene signatures” in breast cancer (Perou, Sorlie et 
al. 2000) provides important prognostic and predictive information (van 't Veer, Dai et al. 
2002; Paik, Shak et al. 2004; Liu, Wang et al. 2007), and holds promise for 
“individualized” molecular therapy of these patients (Sotiriou and Piccart 2007).  
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However, certain subtypes of breast cancer continue to pose therapeutic challenges 
(Sotiriou and Piccart 2007).  For example, basal breast cancer is breast cancer subtype 
characterized by histologic high-grade disease (Da Silva, Clarke et al. 2007), absence of 
HER-2 and receptors for estrogen (ER) and progesterone (Nielsen, Hsu et al. 2004), 
expression of basal cytokeratins (i.e. keratin-5), and proliferation-associated genes 
(Perou, Sorlie et al. 2000; Sotiriou, Neo et al. 2003), as well as defects in genomic 
gatekeepers, p53, or BRCA1 (Sorlie, Perou et al. 2001).  While immunohistochemical 
diagnosis of basal breast cancer is straightforward (Nielsen, Hsu et al. 2004), these 
patients have limited therapeutic options: the response to mainstay chemotherapy is not 
uniform, and affected by the type of drugs used (Cleator, Heller et al. 2007), estrogen or 
HER-2 targeting is not indicated, and attempts to disable ancillary signaling pathways, 
for instance coordinated by the EGF receptor, have so far shown little promise (Baselga, 
Albanell et al. 2005).  This adds to a high rate of relapses that is linked to shortened 
overall survival, and death from disease (Carey, Dees et al. 2007). 
Although the cell of origin of basal breast cancer has not been firmly identified 
(Da Silva, Clarke et al. 2007), a link to the progenitor/stem cell compartment of the 
mammary epithelium has been proposed (Dontu, El-Ashry et al. 2004).  In this context, 
developmental gene expression pathways that control the interplay between cell 
proliferation, survival, and differentiation (Clevers 2006) are candidates for stem cell-
derived mammary tumorigenesis.  One such pathway is centered on the Notch family of 
cell surface receptors (Bray 2006) that affects the mammary stem cell niche (Buono, 
Robinson et al. 2006), and has been associated with malignant transformation (Sansone, 
Storci et al. 2007), and aggressive tumor behavior (Reedijk, Odorcic et al. 2005). 
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Among the candidate effector molecules controlling stem cell viability is survivin, 
a dual regulator of cell division and apoptosis, broadly over-expressed in cancer (Altieri 
2008).  Consistent with its “onco-fetal” pattern of expression, survivin is essential for 
tissue homeostasis (Altieri 2008), and conditional knockout studies have suggested a 
potential critical role of this pathway in maintaining stem cell viability, at least in certain 
tissue compartments (Leung, Xu et al. 2007). 
In this study, we used a combination of hierarchical clustering of a novel 
microarray dataset, meta-analysis of published gene profiling studies, and in vitro 
experiments of gene targeting to investigate a potential role of a Notch-1-survivin 
signaling axis in breast cancer. 
Results 
Differential expression of Notch in breast cancer 
We began this study with preliminary experiments to look at the expression of 
Notch-1 in a representative collection of breast cancer specimens.  An antibody to NIC 
intensely labeled the tumor cell population of invasive breast ductal carcinoma (Figure 
2-1, top panel), infiltrating lobular carcinoma (Figure 2-1, middle panel), and invasive 
papillary carcinoma (Figure 2-1, bottom panel).  In all tumor samples, Notch-1 reactivity 
was observed in both nuclei and cytoplasm of tumor cells (Figure 2-1).  In contrast, 
matched normal breast tissues did not stain for activated Notch-1 (Figure 2-1, right 
panels), and a non-immune IgG gave no staining of normal or breast cancer samples 
(Figure 2-1, insets). 
21 
Expression of Notch in breast cancer microarray databases 
We next analyzed the expression of Notch-1 in an established breast cancer 
patient cohort.  Supervised hierarchical clustering of 232 cases of human breast cancer 
(Herschkowitz, Simin et al. 2007) using “Intrinsic Gene Analysis” revealed that higher 
expression of Notch-1 segregated with basal breast cancer.  Other known markers of the 
disease, including keratin-5 and -14, and kit, were also highly correlated with Notch-1 
expression (r ≥ 0.58) in this cohort (Figure 2-2A).  One hundred twenty five patients with 
associated clinical outcome data were further analyzed.  When stratified according to 
levels of Notch-1 log2 transcript ratios, tumors with the highest quartile of Notch-1 gene 
expression (1st Quartile) exhibited abbreviated overall survival with a median survival of 
27 mo compared to the other groups, p<0.001 via Log-Rank test (Figure 2-2B).  Seventy-
two percent of tumors in this 1st Quartile (23/32) were classified as basal breast cancer, 
and the overall survival of these patients was approximately 50% lower than that of the 
remaining population (p<0.02).  Conversely, reduced levels of Notch-1 (2nd through 4th 
Quartile) were associated with better overall survival (Figure 2-2B).  The percentage of 
basal breast cancers in these groups was 16% (2nd Quartile, 16/31), 19% (3rd Quartile, 
19/31), and 3% (4th Quartile, 3/31), respectively.   
Gene expression correlation in basal breast cancer 
We next carried out a meta-analysis of published microarray datasets to identify 
genes associated with Notch-1, and potentially implicated in the molecular pathogenesis 
of basal breast cancer.  We focused on survivin, a mitotic regulator and cell death 
inhibitor (Altieri 2008) over-expressed in breast cancer (van 't Veer, Dai et al. 2002), and 
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associated with unfavorable outcome (Paik, Shak et al. 2004), and keratin-5, a marker of 
basal epithelium, often linked to a progenitor/stem cell phenotype (Dontu, El-Ashry et al. 
2004).  Fifteen microarray datasets, mostly employing Affymetrix technology published 
between 2002 and 2007, fulfilled the search criteria (Table 2-1).  The overall median age 
of patients was 55.2 years.  The breast tumors examined were typically <5 cm, 
encompassing all grades, and included lymph node-positive and lymph node-negative 
disease.  In one study (Zhao, Langerod et al. 2004) separate databases for lobular and 
ductal breast cancer were examined, bringing the datasets analyzed to a total of 16.  Two 
studies (Zhao, Langerod et al. 2004; Saal, Johansson et al. 2007) did not contain 
downloadable keratin-5 expression data, and one study (Yu, Ganesan et al. 2006) 
contained 68 out of 96 samples with Notch-1 and survivin data, and 19 samples with 
keratin-5 data.  Table 2-2 shows the descriptive statistics of each cohort with respect to 
Notch-1, survivin, and keratin-5 relative expression. 
A novel dual gene signature in basal breast cancer 
Analysis of 507 ER-negative and 1356 ER-positive breast cancer patients 
revealed that keratin-5 associated with ER-negative breast cancers (Figure 2-3A) in 7 out 
of 13 data sets, and that Notch-1 associated with ER-negative breast cancers in 9 out of 
16 datasets (Table 2-2).  Pooled estimates of Pearson’s correlation coefficient between 
Notch-1/keratin-5 were 0.3315 and 0.2043, for ER-negative and ER-positive breast 
cancers, respectively, p=0.04 (Figure 2-3A).  Similarly, survivin and keratin-5 co-
segregated in ER-negative breast cancer, with a pooled estimate of Pearson’s correlation 
coefficient of 0.1314 for ER-negative and -0.2408 for ER-positive breast cancers, 
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p<0.0001 (Figure 2-3B).  Analysis of 604 ER-negative and 1463 ER-positive breast 
cancer patients revealed that survivin segregated with ER-negative tumors (two-tailed 
p<0.05) in 12 out of 16 cohorts (Table 2-2).  The Pearson’s correlation coefficients 
between Notch-1 and survivin were 0.1804 and -0.0674 for ER-negative and ER-positive 
breast cancers, respectively, p<0.0001 (Figure 2-3C). 
Notch-1 regulation of survivin expression   
Recent studies have shown that survivin may function as a direct transcriptional 
target of Notch-1, thus controlling mitotic transition and resistance to apoptosis in breast 
cancer (Lee, Raskett et al. 2008).  Transfection of model ER- breast cancer MDA-MB-
231 cells with NIC resulted in increased survivin expression, by Western blotting (Figure 
2-4A).  Bcl-2, a known downstream target of Notch, and XIAP, a cofactor that is 
stabilized by survivin in protection from apoptosis, were also increased after NIC 
transfection (Figure 2-4A).  In parallel experiments, targeting Notch by small interfering 
RNA (siRNA) resulted in a ~50% reduction in endogenous Notch-1 expression, by 
Western blotting (Figure 2-4B).  This was associated with concomitant reduction of 
survivin levels in MDA-MB-231 cells, by Western blotting (Figure 2-4B), and reduction 
of cell viability (Supplemental Figure 2-5), whereas acute ablation of survivin by siRNA 
did not affect Notch-1 levels (Figure 2-4B).  Activation of Notch signaling requires 
cleavage by the enzyme γ-secretase, and this step is inhibited by pharmacologic γ-
secretase inhibitors (GSI).  Treatment of MDA-MB-231 cells with a peptidyl GSI, z-Leu-
Leu-Nle-CHO resulted in reduction of survivin, XIAP, and Bcl-2 expression levels, by 
Western blotting (Figure 2-4C), in agreement with recent observations (Lee, Raskett et al. 
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2008).  To validate that survivin is a direct downstream transcriptional target of Notch 
(Lee, Raskett et al. 2008), we next stably transfected MDA-MB-231 cell line to express a 
GFP reporter gene under the control of the proximal, 830 nt mouse survivin promoter 
(MDA-MB-231 ms-830-GFP).  Treatment of MDA-MB-231 ms-830-GFP stable cells 
with 1 µM of GSI was associated with a significant reduction of GFP expression, as 
assessed by flow cytometry (Figure 2-4D).   
Discussion 
In this study, we have shown that Notch-1 is preferentially expressed in breast 
cancer, as compared with normal tissues, segregates with basal disease, and correlates 
with abbreviated survival.  In meta-analysis of multiple, independent microarray datasets, 
Notch-1, survivin, and keratin-5 selectively co-associated with ER-negative versus ER-
positive breast cancer patients.  In model ER- breast cancer cells, survivin was validated 
as a direct transcriptional target of Notch, and targeting this pathway by genetic or 
pharmacologic approaches reduced the expression of survivin, as well as of other 
apoptotic regulators, including XIAP and Bcl-2.  
These findings add to an in-depth molecular classification of breast cancer 
(Sotiriou and Piccart 2007), and in particular, basal breast cancer, a disease variant that 
still poses significant therapeutic challenges.  In addition to high-risk genetics (Perou, 
Sorlie et al. 2000; Sotiriou, Neo et al. 2003) and aggressive histologic features (Da Silva, 
Clarke et al. 2007), it has been speculated that basal breast cancer may originate from a 
progenitor/stem cell compartment in the basal mammary epithelium.  This is consistent 
with a proposed role of Notch in stem cell maintenance (Bray 2006), and potentially in 
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the early events of their transformation (Farnie, Clarke et al. 2007).  Such a pathway may 
not be exclusively limited to breast cancer (Stylianou, Clarke et al. 2006), given that 
deregulated Notch signaling has been implicated as a “driver” of disparate malignancies 
(Bray 2006), promoting aberrant cell cycle progression (Ronchini and Capobianco 2001), 
and unfavorable outcome (Reedijk, Odorcic et al. 2005). 
In this context, survivin appears ideally suited to function as a pleiotropic, direct 
Notch effector gene in clinically aggressive breast cancer (Paik, Shak et al. 2004).  At the 
molecular level, this involves transcription from discrete RPB-Jκ binding element(s) in 
the survivin promoter upon Notch activation that results in transcriptional upregulation of 
survivin levels, inhibition of apoptosis, and acceleration of mitotic transitions selectively 
in ER- breast cancer cells (Lee, Raskett et al. 2008).  Whether deregulation of a Notch-
survivin signaling axis is preferentially operative in a progenitor/stem cell compartment 
is currently not known.  However, it is intriguing that another developmental gene 
expression pathway, i.e. Wnt/β-catenin has been implicated in controlling survivin levels 
in intestinal crypt progenitor cells, potentially contributing to colon cancer (Kim, Plescia 
et al. 2003), and that survivin expression been consistently associated with ‘stemness’ 
gene signatures of mesenchymal (Taubert, Wurl et al. 2007), neuronal (Pennartz, 
Belvindrah et al. 2004), and skin (Marconi, Dallaglio et al. 2006) progenitor cells.  
Results of conditional knockout studies appear to support this model, as heterozygous 
deletion of survivin produced complete bone marrow ablation, loss of hematopoietic 
progenitor/stem cells, and rapid animal mortality (Leung, Xu et al. 2007).  This pathway 
may have a clear link to human disease, as lineage-specific methylation and silencing of 
the survivin gene has been linked to bone marrow depletion in myelodsyplastic syndrome 
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(Hopfer, Komor et al. 2007).  With respect to breast cancer, and consistent with recent 
observations (Lee, Raskett et al. 2008), Notch-dependent upregulation of survivin (and 
potentially Bcl-2 and XIAP) may broadly suppress apoptosis, deregulate cell cycle 
progression (Altieri 2008), and ultimately promote resistance to mainstay therapeutic 
agents in this disease, such as taxanes (O'Connor, Wall et al. 2002), and DNA damaging 
agents (Ghosh, Dohi et al. 2006). 
Although the diagnosis of “triple negative”, basal breast cancer is straightforward 
(Nielsen, Hsu et al. 2004), these patients continue to pose therapeutic challenges because 
of the aggressive nature of the disease.  Basal breast cancers often present in younger 
patients with a high grade disease.  While the cancers respond initially to chemotherapy, 
the cancers are prone to relapse, reducing overall survival.  Furthermore, these patients 
lack appropriate, molecularly-targeted agents for their disease (Cleator, Heller et al. 
2007).  Based on the findings presented here, it may be possible to envision antagonists 
of Notch (Shih Ie and Wang 2007), and survivin (Altieri 2008) as potential molecular 
therapy for basal breast cancer patients.  Agents that interfere with Notch signaling 
inhibit the enzyme γ-secretase, which is responsible for the activating intracellular 
cleavage of Notch upon ligand binding at the cell surface (Bray 2006).  Despite concerns 
of specificity (Fortini 2002), and potential intestinal toxicity (Wong, Manfra et al. 2004), 
GSI molecules are being tested as molecular therapy in leukemia patients harboring 
activating mutations in Notch (Shih Ie and Wang 2007).  In our recent studies, systemic 
administration of a peptidyl GSI significantly inhibited breast cancer growth in vivo, and 
nearly completely abolished metastatic dissemination, with no detectable organ or 
systemic toxicity (Lee, Raskett et al. 2008).  Antagonists of survivin are also available in 
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the clinic, producing encouraging patient responses and manageable toxicity in early 
phase clinical trials (Altieri 2008). 
In summary, we have extended initial in vitro experiments (Lee, Raskett et al. 
2008), and validated the existence of a functional Notch-1/survivin signaling axis 
selectively in patients with basal breast cancer.  Targeting Notch-1 signaling in model 
breast cancer cells lowered survivin levels, resulting in pronounced anti-tumor effects 
(Lee, Raskett et al. 2008).  Taken together with the stringent correlation reported here 
across disparate tumor series, this raises the possibility that basal breast cancer cells may 
selectively become dependent, or “addicted” to Notch/survivin signaling for their 
maintenance (Weinstein and Joe 2006).  Although it is unclear to what extent “oncogene 
addiction” maintains the malignant phenotype in vivo (Jonkers and Berns 2004), 
antagonists of such pathways have produced impressive clinical responses, at least in 
certain patient subsets (Sharma, Bell et al. 2007).  A similar rationale may be envisioned 
here for targeting Notch and survivin in basal breast cancer patients, especially if this 
pathway can be disabled in a progenitor/stem cell compartment, acting as a potential 
disease reservoir contributing to a high incidence of relapses. 
Material and Methods 
Immunohistochemistry 
Nine cases of human breast cancer and matched normal breast tissue from the 
same patient were obtained from the University of Massachusetts Cancer Center Tissue 
Bank.  Tissue sections (5-µm) from paraffin blocks were cut, deparaffinized in xylene, 
rehydrated, and baked overnight at 60°C.  Slides were quenched for endogenous 
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peroxidase with 3% H2O2 in methanol for 20 min, and processed for antigen retrieval by 
pressure cooking in 9 mM sodium citrate, pH 6.0, for 20 min.  Slides were washed in 
PBS, and incubated overnight at 4°C with a rabbit antibody to Notch-1 intracellular 
domain (NIC) or control IgG, rinsed, and incubated with a biotinylated anti-rabbit IgG 
for 10 min at 22°C.  After addition of streptavidin-conjugated horseradish peroxidase, 
slides were incubated with 3'-3'-diamino-benzidine (DAB) for 3-10 min, and 
counterstained with hematoxylin, as described (Dohi, Beltrami et al. 2004). 
Hierarchical clustering analysis of Notch-1 expression in breast cancer  
The log2 Cy5/Cy3 ratios of 232 cases of human breast cancer and their associated 
clinical data were downloaded from https://genome.unc.edu (Herschkowitz, Simin et al. 
2007).  Only genes where the Lowess normalized intensity values in both channels were 
>30, and data in >70% samples were included for analysis.  The gene set was further 
filtered to include only genes with Pearson’s correlation coefficient >0.58 with Notch-1 
(n=101).  Two-way hierarchical clustering was performed using Cluster v3 (Eisen, 
Spellman et al. 1998), and the results displayed using JavaTreeview (Saldanha 2004).  
Analysis of overall survival (Log-Rank test) was carried out using JMP 6.0 out on the 
subset of breast cancer patients in this cohort with available clinical data (n=125).  Data 
were plotted for each quartile of normalized Notch-1 log2 ratios, from highest (1st 
Quartile) to lowest (4th Quartile). 
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Meta-analysis of Oncomine microarray data 
We reviewed Oncomine (http://www.oncomine.org) (Rhodes, Yu et al. 2004) for 
independent human breast cancer microarray datasets comparing ER-negative and ER-
positive tumors.  Databases from 15 studies were found to contain Notch-1 and survivin 
relative expression data.  The patient characteristics and analyses performed in each study 
are summarized in Table 2-1.  Descriptive statistics including mean, standard error, and a 
two-tailed unpaired t-test were calculated for the comparisons between ER-positive and 
ER-negative samples within each study.  Separately for ER-negative and ER-positive 
samples, a Pearson’s correlation coefficient (r) was calculated for each study to measure 
levels of pair-wise co-expression between Notch-1, survivin, and keratin-5.  The 95% 
confidence interval for r was calculated based on Fisher’s Z transformation (Kleibaum, 
Kupper et al. 1998).  In one study (Turashvili, Bouchal et al. 2007), a Fisher’s Z 
transformation could not be performed for ER-negative samples (n=3), and an 
approximate variance for a Pearson’s correlation coefficient was used to derive its 95% 
confidence interval.  To summarize ER-specific results from the individual studies, 
Fisher’s Z transformation and its variance were used in pooling correlation from different 
studies.  Weighted-average of Fisher’s Z transformation and its 95% confidence interval 
were first estimated based on a fixed-effect model, taking into account the variance 
associated with each study.  ER-specific pooled estimate of Pearson’s correlation 
coefficient and its 95% confidence interval were then derived from the estimates based 
on the Fisher’s Z transformation.  We applied a random-effect model for meta-analysis 
(DerSimonian and Laird 1986) to evaluate whether levels of co-expressions between 
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Notch-1, survivin, and keratin-5 differ between ER-negative and ER-positive samples 
among the different studies. 
Cells and reagents  
The breast adenocarcinoma MDA-MB-231 cell line was obtained from the 
American Type Culture Collection (ATCC, Manassas, VA), and maintained in culture as 
recommended by the supplier.  An 830 nt fragment of the mouse survivin promoter fused 
upstream of a Green Fluorescence Protein (GFP) reporter gene (ms-830-GFP) was 
described previously (Xia and Altieri 2006).  To generate a stable cell line expressing ms-
830-GFP, MDA-MB-231 cells were transfected by Lipofectamine (Invitrogen), and 
selected in medium containing 1 mg/ml Zeocin (Invitrogen).  A peptidyl γ-secretase 
inhibitor (GSI) z-Leu-Leu-Nle-CHO was purchased from Calbiochem (San Diego, CA), 
and characterized in recent studies (Lee, Raskett et al. 2008).  
Transfections 
A cDNA encoding activated NIC was characterized previously (Small, Kovalenko 
et al. 2001).  MDA-MB-231 cells were transfected with pcDNA or NIC cDNA (2 µg) 
using 6 µl LipofectAmine (Invitrogen) in Opti-Mem medium (1 ml) (Gibco).  The media 
was changed after 5 h, and cells were harvested after 24 h.  For gene silencing 
experiments by small interfering RNA (siRNA), MDA-MB-231 cells were transfected 
with double stranded (ds) RNA oligonucleotide directed to Notch-1, survivin, or control 
non-targeted sequences using 10 µl HiPerfect (Gibco).  Cells under the various conditions 
were harvested after 48 h, and analyzed by Western blotting. 
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Table 2-1.  Published datasets included in meta-analysis.   
Sixteen datasets derived from an unbiased search of human breast cancer microarrays on 
Oncomine were identified that matched study criteria. 
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Table 2-2.  Descriptive statistics of studies in meta-analysis.   
Mean, SEM, and p-value between ER-negative and ER-positive breast cancers are shown 
for Notch-1, survivin, and keratin-5.   
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Figure 2-1.  Differential expression of activated Notch-1 in breast cancer. 
Representative breast cancer cases of invasive ductal cell carcinoma (top panel), 
infiltrating lobular cell carcinoma (middle panel), and invasive papillary carcinoma 
(bottom panel), or normal breast (normal) were analyzed by immunohistochemistry.  Left 
panels, 10x; middle panels, 40x, right panels, 10x.   
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Figure 2-2.  Notch-1 segregates with basal breast cancer.   
A. Heat map of 232 cases of breast cancer.  Color code: Luminal A, green; Luminal B, 
yellow; Normal Breast-like, white; HER-2+/ER-, red; Basal, blue; Unclassified, gray.  B. 
Kaplan-Meier curves.   
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Figure 2-3.  Co-segregation of Notch-1, survivin, and keratin-5 in breast cancer. 
Pearson’s correlation coefficient and 95% confidence interval were calculated.  A. Notch-
1/keratin-5.  B. Survivin/keratin-5.  C. Notch-1/survivin. 
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Figure 2-4.  Notch-1 modulation of survivin expression.   
A. Plasmid transfection. MDA-MB-231 cells were transfected with NIC or control 
pcDNA, and analyzed by Western blotting.  B. siRNA transfection.  MDA-MB-231 cells 
were transfected with control, survivin, or Notch-1 siRNA and analyzed by Western 
blotting.  For panels A and B, numbers correspond to normalized densitometric 
quantification of survivin or Notch-1 protein bands.  C. GSI-mediated Notch inhibition.  
MDA-MB-231 cells were treated with GSI for 24 h, and analyzed by Western blotting.  
D. GSI inhibits survivin promoter activity.  MDA-MB-231 stably transfected with ms-
830-GFP were treated with 1 µM GSI for 24 h, and analyzed for GFP expression by flow 
cytometry. 
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Supplemental Figure 2-5.  Knockdown of Notch-1. 
Metabolic MTT Assay of Notch-1 knockdown.  Mean±SEM, n=4, p=0.04 
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Chapter 3. Molecular dependence of estrogen receptor negative 
breast cancer on a Notch-survivin signaling axis 
Connie W. Lee, Christopher M. Raskett, Igor Prudovsky, and Dario C. Altieri 
This chapter represents collaboration amongst the listed authors.  The text is a 
version of the manuscript accepted by Cancer Research on May 20, 2008 (Lee, Raskett et 
al. 2008).  I participated in all aspects of the project development.  Christopher Raskett 
provided support in the in vivo murine experiments.  Igor Prudovsky provided the initial 
Notch reagents.  Dario Altieri helped conceive and design the study.  I wrote the first 
drafts of the introduction, results, and material and methods.  Dario Altieri revised the 
text while I provided feedback.   
Abstract 
Despite progress in the management of breast cancer, the molecular 
underpinnings of clinically aggressive subtypes of the disease are not well understood.  
Here, we show that activation of Notch developmental signaling in estrogen receptor 
(ER)-negative breast cancer cells results in direct transcriptional upregulation of the 
apoptosis inhibitor and cell cycle regulator, survivin.  This response is associated with 
increased expression of survivin at mitosis, enhanced cell proliferation, and heightened 
viability at cell division.  Conversely, targeting Notch signaling with a peptidyl γ-
secretase inhibitor suppressed survivin levels, induced apoptosis, abolished colony 
formation in soft agar, and inhibited localized and metastatic tumor growth in mice, 
without organ or systemic toxicity.  In contrast, ER+ breast cancer cells, or various 
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normal cell types, were insensitive to Notch stimulation.  Therefore, ER- breast cancer 
cells become dependent on Notch-survivin signaling for their maintenance, in vivo.  
Therapeutic targeting of this pathway may be explored for individualized treatment of 
clinically aggressive, ER- breast cancer patients.  
Introduction 
Despite the success of “targeted” agents (Hudis 2007), including estrogen ablation 
(Jordan 2007), breast cancer remains a potentially deadly disease, marked by 
extraordinary molecular and clinical heterogeneity (Perou, Sorlie et al. 2000).  Gene 
expression signatures have been useful to catalog the different molecular subtypes of 
breast cancer, and, in some cases, this information carries important prognostic (van 't 
Veer, Dai et al. 2002; Liu, Wang et al. 2007), and predictive (Paik, Shak et al. 2004) 
value to identify patients at risk of recurrent disease (Sotiriou and Piccart 2007).  
However, the molecular pathways underlying clinically aggressive variants of breast 
cancer, typically estrogen receptor (ER)-negative disease, have not been identified 
(Nahta, Yu et al. 2006), and “individualized” therapy for these patients based on 
molecular disease profile is not presently available. 
Developmental signaling pathways, such as Notch, are critical for tissue 
specification and organ morphogenesis (Clevers 2006), and are frequently deregulated in 
cancer (Taipale and Beachy 2001).  Although it remains to be seen to what extent these 
mechanisms are truly disease “drivers”, mutations in Notch-1 (Weng, Ferrando et al. 
2004) cause oncogene expression in a subset of T-cell acute lymphoblastic leukemia 
(Sharma, Calvo et al. 2006; Weng, Millholland et al. 2006), and deregulated Notch 
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activity may influence cellular transformation (Stylianou, Clarke et al. 2006), cell cycle 
dynamics (Ronchini and Capobianco 2001), progenitor/stem cell maintenance (Farnie, 
Clarke et al. 2007), and disease outcome (Reedijk, Odorcic et al. 2005) in breast cancer.  
Notch signaling initiates with the binding of extracellular ligands, Jagged-1, -2, Delta-
like-1, -3, or -4, to Notch receptors at the cell surface.  In turns, this results in proteolytic 
cleavage of Notch intracellular domain (NIC) by the enzyme γ-secretase, nuclear import 
of NIC, and recruitment of transcriptional modulators, including RBP-Jκ, to drive de 
novo expression of target genes (Bray 2006).  Although it is clear that Notch and other 
developmental pathways control multiple downstream networks of cell proliferation, cell 
survival, and progenitor/stem cell maintenance (Clevers 2006), only a handful of target 
genes capable of orchestrating such pleiotropic responses has been identified, and their 
contribution to the cancer phenotype has remained largely elusive. 
As a unique member of the Inhibitor of Apoptosis (IAP) gene family (Eckelman, 
Salvesen et al. 2006), survivin has emerged as a pivotal cancer gene with multiple roles in 
the regulation of mitosis, suppression of cell death, and enhanced adaptation to cellular 
stress (Altieri 2003).  The sharp differential expression of survivin in cancer, as opposed 
to normal tissues, is largely controlled at the level of transcription, and several oncogenic 
pathways, including developmental signaling by Wnt/β-catenin (Kim, Plescia et al. 
2003), have been shown to promote survivin gene expression.  There is also evidence that 
survivin may be a critical gene in breast cancer, linked to aggressive disease (Paik, Shak 
et al. 2004), resistance to apoptosis (Gritsko, Williams et al. 2006), and modulation of 
ErbB2 signaling (Xia, Bisi et al. 2006). 
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In this study, we mapped novel molecular circuitries of breast cancer 
pathogenesis.  We found that survivin is a novel target of Notch signaling, and this occurs 
preferentially in ER- breast cancer cells.  Therapeutic targeting of a Notch-survivin axis 
produces strong anticancer activity, and is well tolerated in vivo, opening new 
opportunities for “individualized” therapy in clinically aggressive breast cancer subtypes. 
Results 
Notch-1 induction of survivin in estrogen receptor negative breast cancers 
Preliminary meta-analysis of published microarray data (Sorlie, Perou et al. 2001; 
van de Vijver, He et al. 2002; Zhao, Langerod et al. 2004; Miller, Smeds et al. 2005; 
Minn, Gupta et al. 2005; Wang, Klijn et al. 2005; Chin, DeVries et al. 2006; Ginestier, 
Cervera et al. 2006; Hess, Anderson et al. 2006; Ivshina, George et al. 2006; Richardson, 
Wang et al. 2006; Sotiriou, Wirapati et al. 2006; Yu, Ganesan et al. 2006; Desmedt, 
Piette et al. 2007; Saal, Johansson et al. 2007; Turashvili, Bouchal et al. 2007) revealed 
that Notch-1 and survivin co-segregated with ER- breast cancer cases, and correlated with 
abbreviated overall survival (unpublished observations).  Consistent with this, 
transduction of ER- breast adenocarcinoma MDA-MB-231, HBL100, and Sum149 cells 
(Neve, Chin et al. 2006) with pAd-NIC, the active intracellular domain of Notch, resulted 
in a 1.5-2-fold increased survivin mRNA expression, as compared with pAd-GFP-treated 
cultures (Figure 3-1A).  In contrast, Notch stimulation of ER+ breast cancer cells MCF-7 
and T47D, or normal HMECs, did not modulate survivin mRNA levels (Figure 3-1A).  In 
time-course experiments, pAd-NIC increased expression of survivin in ER- MDA-MB-
231 cells, but not ER+ MCF-7 cells, by Western blotting (Figure 3-1B).  Semi-
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quantitative Western blotting verifies the selective increase of survivin after Notch 
activation in MDA-MB-231 cells compared to MCF-7 cells (Supplemental Figure 3-8).  
Conversely, Bcl-2 was comparably upregulated in both cell types (Wang, Zhang et al. 
2006), whereas another survival factor, XIAP, was not significantly affected (Figure 
3-1B).  Even a prolonged, 72 h, stimulation of normal primary human mammary 
epithelial cells with pAd-NIC did not modulate survivin or XIAP expression (Figure 
3-1C).  Knockdown of Notch-1 by ~50% in MDA-MB-231 breast cancer cells 
corresponded with ~50% decrease in survivin protein levels (Figure 2-4D) and a 34% 
reduction in cellular viability (Supplemental Figure 2-5). 
Notch-1 regulation of survivin gene expression 
To determine whether Notch directly stimulated survivin gene expression, we 
next used an 830 bp fragment of the survivin promoter fused to Green Fluorescent Protein 
(GFP), i.e. ms-830-GFP (Xia and Altieri 2006), containing two putative RBP-Jκ sites 
(Bray 2006) at -543 and -355 (Figure 3-2A).  Co-transfection of Notch-1 or Jagged-1 
together with wild type ms-830-GFP resulted in strong expression of GFP, by Western 
blotting (Figure 3-2B), and quantitative fluorescence microscopy (Figure 3-2C, upper 
panel), as compared with pcDNA3-expressing cells (Figure 3-2C, upper panel).  
Mutation of the proximal RBP-Jκ site at -355 in ms-830-GFP (Figure 3-2A) abolished 
Notch-1 induction of GFP to background levels of control cultures (Figure 3-2C, lower 
panel).  By EMSA, a radiolabeled probe of the -355 RBP-Jκ site formed DNA-protein 
complexes in MDA-MB-231 nuclear extracts (Figure 3-2D).  This interaction was 
competed out by equimolar concentrations of unlabeled probe, or a canonical Hes RBP-
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Jκ sequence, but not by an unrelated competitor (Figure 3-2D).  Similarly, a radiolabeled 
Hes RBP-Jκ  probe bound to MDA-MB-231 nuclear extracts, in a reaction also competed 
out by molar excess of unlabeled probe (Figure 3-2D).  In contrast, a probe of the -543 
survivin RBP-Jκ site did not form DNA-protein complexes in MDA-MB-231 extracts 
(data not shown), and was not further investigated.  Consistent with these data, ChIP 
experiments using MDA-MB-231 cells transduced with pAd-NIC revealed that RNA 
polymerase II and RBP-Jκ were physically associated with the human survivin promoter 
in vivo at the putative RBP-Jκ binding site at -305 (Figure 3-3B). 
Notch-1 regulation of cell proliferation 
To determine the kinetics of Notch-1 induction of survivin, we next studied cell 
cycle transitions in synchronized MDA-MB-231 cells after transduction with pAd-NIC.  
In synchronized cultures expressing pAd-GFP, endogenous survivin was expressed in a 
cell cycle-dependent manner, peaking at mitosis, 8- to 12-h after thymidine release 
(Figure 3-4A), consistent with previous observations (O'Connor, Wall et al. 2002).  In 
these cells, Notch-1 increased survivin with the same kinetics, in a reaction that was 
maximal at mitosis (Figure 3-4A).  Quantification of cell cycle phases revealed that GFP-
expressing cells approached S-phase 4 h after thymidine release, entered mitosis after 8 h, 
and completed cell division between 10 and 12 h, with re-accumulation in the next G1 
phase by 14 h (Figure 3-4B).  In contrast, Notch activation resulted in accelerated mitotic 
transitions, with 30% of NIC-expressing cells exiting mitosis 10 h after release, as 
compared with 17% of GFP-transduced cells, and 64% of Notch-1-stimulated cells re-
entering G1 after 14 h, versus 40% of control cultures (Figure 3-4B).  Accelerated mitotic 
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progression in Notch-stimulated MDA-MB-231 cells was associated with increased cell 
proliferation over a 6-d interval, as compared with pAd-GFP-expressing cultures (Figure 
3-4C).  In contrast, pAd-NIC or pAd-GFP did not induce changes in cell proliferation in 
ER+ MCF-7 cultures (Figure 3-4C). 
We next asked whether Notch-1 induction of survivin was important for cell 
viability during this proliferative response.  For these experiments, we transduced MDA-
MB-231 cells with a dominant negative survivin mutant (pAd-T34A), which interferes 
with the mitotic function of survivin (O'Connor, Wall et al. 2002).  Expression of pAd-
T34A had no effect on synchronized, interphase cultures, but caused acute loss of cell 
viability as cells progressed through mitosis (Figure 3-4D), in agreement with previous 
observations (O'Connor, Wall et al. 2002).  Notch stimulation reversed pAd-T34A-
induced cell death, and preserved cell viability at mitosis (Figure 3-4D).  In control 
experiments, pAd-NIC had no effect on MDA-MB-231 cell viability (Figure 3-4D).  The 
higher number of cells with >4N DNA content after pAd-NIC transduction may reflect 
mitotic slippage and accumulation of chromosomal abnormalities due to accelerated 
mitotic transition. 
Effect of Notch targeting on breast cancer viability 
To test the impact of Notch signaling in breast cancer, we used a GSI z-Leu-Leu-
Nle-CHO, which inhibits receptor cleavage and NIC generation (Bray 2006).  GSI 
treatment reduced endogenous survivin levels in MDA-MB-231 cells, and this was 
associated with parallel suppression of Bcl-2, and XIAP (Figure 3-5A).  In contrast, GSI 
minimally affected the expression of these anti-apoptotic molecules in MCF-7 cells 
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(Figure 3-5A).  In addition, GSI had no effect on survivin levels in WS-1 fibroblasts or 
INT colonic epithelial cells, whereas XIAP was modestly reduced (Liu, Hsiao et al. 
2007), and Bcl-2 was undetectable in these cells (Figure 3-5A).  Treatment of MDA-MB-
231 cells with a second, structurally independent GSI molecule, z-Ile-Leu-CHO, reduced 
Notch-1 expression, and attenuated survivin levels in MDA-MB-231 cells (Supplemental 
Figure 3-9). 
Transduction of MDA-MB-231 cells with pAd control or pAd-NIC did not 
significantly affect cell viability, as determined by DEVDase, i.e. caspase, activity and 
multiparametric flow cytometry (Figure 3-5B, top panels).  GSI treatment of these cells 
resulted in a 2-fold increase in the fraction of apoptotic cells, in a reaction nearly 
completely reversed by pAd-NIC (Figure 3-5B, top panels).  In contrast, GSI did not 
significantly induce caspase activity in MCF-7 cultures, and transduction of these cells 
with pAd-NIC or pAd-Control had no further effect on cell viability (Figure 3-5B, lower 
panels).  Consistent with these data, GSI induced concentration-dependent killing of 
multiple ER- breast cancer cell types, including MDA-MB-231, HBL100, Sum149 
(Figure 3-5C, left panel) with IC50 <3.5 µM.  Comparatively, ER+ cell types, MCF-7 and 
T47D, were less sensitive to GSI-induced killing, with IC50 concentrations of >10 µM 
and 5.907 µM, respectively (Figure 3-5C, middle panel).  In addition, comparable 
concentrations of GSI did not affect the viability of three primary fibroblast cell lines, 
(WS-1, HFF, and HGF), normal INT epithelial cells, or primary human mammary 
epithelial cells (Figure 3-5C, right panel).   
To further investigate the anti-tumor effects of GSI, we next tested the effect of 
Notch inhibition on a panel of tumor cell lines.  Treatment of prostate adenocarcinoma 
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PC3, lung adenocarcinoma H1975, or squamous cell carcinoma A431 cells with GSI 
resulted in concentration-dependent cell death, quantitatively similar to that observed 
with MDA-MB-231 cells (Supplemental Figure 3-10).  Conversely, prostate 
adenocarcinoma DU145, lung adenocarcinoma H460, colorectal adenocarcinoma 
HCT116, or glioblastoma U87MG cells were largely resistant to GSI-induced cell death 
(Supplemental Figure 3-10).   
GSI induction of apoptosis in breast cancer cell lines 
MDA-MB-231 cells exposed to GSI exhibited morphologic hallmarks of 
apoptosis, including chromatin condensation and fragmentation (Figure 3-6A, left panel), 
and concentration-dependent release of cytochrome c in the cytosol (Figure 3-6A, right 
panel).  GSI-induced cell death under these conditions was fully reversed by a broad 
spectrum caspase inhibitor, zVAD, comparable to its inhibition of STS-induced apoptosis 
(Figure 3-6B).  In contrast, GSI did not affect cell viability or cytochrome c release in 
MCF-7 cultures (Figure 3-6A).  To test whether loss of survivin after Notch inhibition 
contributed to apoptosis, we transduced MDA-MB-231 cells with pAd-GFP or pAd-
Survivin, and quantified GSI-induced cell death.  In GFP-expressing cells, GSI induced a 
sustained G2/M arrest, and apoptosis (Figure 3-6C).  Expression of survivin in these cells 
did not significantly affect the mitotic arrest imposed by Notch inhibition, but completely 
reversed GSI-induced cell death, whereas pAd-GFP was ineffective (Figure 3-6C). 
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Targeting Notch signaling for breast cancer therapy 
GSI treatment of MDA-MB-231 cells abolished colony formation in soft agar 
(Figure 3-6D, left panel), whereas comparable concentrations of GSI were 3 orders of 
magnitude less effective in MCF-7 cells (Figure 3-6D, right panel).  Survivin can rescue 
ablation of colony formation by low doses of GSI (<0.5 µM) (Supplemental Figure 3-11) 
but not at doses of GSI > 1 µM (data not shown).  Next, we grew MDA-MB-231 cells as 
superficial tumors in immunocompromised mice, and treated the animals with vehicle or 
systemic GSI (3 mg/kg/daily i.p.).  In control animals, MDA-MB-231 tumors grew at a 
steady exponential rate over a two week time interval (Figure 3-7A).  In contrast, GSI 
treatment significantly inhibited tumor growth over a comparable time interval (Figure 
3-7A).  In addition, lungs from mice treated with vehicle exhibited a high density of 
epithelial micrometastases (Fraker, Halter et al. 1984), by hematoxylin-eosin staining of 
serial lung sections (Figure 3-7B, left panel).  In contrast, GSI treatment inhibited 
formation of lung metastases, in vivo (Figure 3-7B, right panel). 
Safety of Notch targeting for cancer therapy 
Mice in the GSI group did not exhibit signs of systemic toxicity, and had no 
significant weight loss, as compared with vehicle-treated animals (Supplemental Figure 
3-12).  Histologic examination of lung, colon, pancreas, spleen, kidney, and liver was 
largely indistinguishable in control or GSI-treated mice (Figure 3-7C).  Specifically, lung 
sections from GSI or control group showed a conserved architecture with a normal 
alveolar septum, absence of lymphatic dilatation, or interstitial inflammation (Figure 
3-7C).  With respect to the gastrointestinal tract, GSI treatment did not cause goblet cell 
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hyperplasia of colonic epithelium, and resulted in only mild fasciitis of pancreatic tissue, 
as compared with vehicle-treated control (Figure 3-7C).  The liver architecture of hepatic 
nodules was fully preserved in GSI-treated animals, without steatosis or inflammatory 
infiltration, and extramedullary hematopoiesis was comparably observed in control- or 
GSI-treated animals (Figure 3-7C). 
Discussion 
In this study, we have shown that Notch signaling increases cell proliferation and 
promotes resistance to apoptosis preferentially in ER- breast cancer (Yehiely, Moyano et 
al. 2006), a disease subtype often marked by aggressive clinical behavior (Sorlie, Perou et 
al. 2001).  A critical effector of this pathway was identified as survivin, a pleiotropic 
regulator of cell proliferation and inhibitor of apoptosis over-expressed in many cancers 
(Altieri 2003).  Conversely, inhibition of Notch signaling with a peptidyl GSI 
downregulated survivin, inhibited cell proliferation, increased apoptosis, and suppressed 
the growth of localized and metastatic ER- breast cancer in mice, without overt toxicity. 
Recently, there has been considerable interest in elucidating how developmental 
signaling pathways, including Notch (Bray 2006) may aberrantly contribute to 
tumorigenesis.  Mounting evidence suggests that Notch deregulation may engender 
critical tumor hallmarks, including oncogene expression (Sharma, Calvo et al. 2006; 
Weng, Millholland et al. 2006), angiogenesis, (Keith and Simon 2007), stem cell 
maintenance (van Es, van Gijn et al. 2005), deregulated cell cycle progression (Ronchini 
and Capobianco 2001), and anti-apoptotic mechanisms (Beverly, Felsher et al. 2005; Liu, 
Hsiao et al. 2007).  In this context, survivin fits well the pleiotropic requirements of a 
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Notch effector gene for its essential roles in mitosis (Lens, Vader et al. 2006), 
preservation of stem/progenitor cell homeostasis (Leung, Xu et al. 2007), inhibition of 
apoptosis (Dohi, Xia et al. 2007), and regulation of angiogenesis (Singh, Dhanalakshmi et 
al. 2005).  Mechanistically, Notch stimulation resulted in direct activation of survivin 
gene transcription through at least one RPB-Jκ site (Bray 2006) in the survivin promoter.  
This is reminiscent of how another developmental signaling program, i.e. Wnt/β-catenin, 
directly induces survivin gene transcription in cancer (Kim, Plescia et al. 2003).  
Consistent with the known tissue specificity of Notch signaling that has been associated 
with malignant transformation (Weng, Ferrando et al. 2004), or tumor suppression 
(Nicolas, Wolfer et al. 2003) depending on the tissue, a Notch-survivin axis was 
preferentially operative in ER- versus ER+ breast cancer cells, and not at all detected in 
various normal cell types. 
Three potential mechanisms may be envisioned for a role of survivin as a Notch 
target in clinically aggressive breast cancer (Sorlie, Perou et al. 2001).  First, Notch-
induced heightened survivin levels at mitosis may deregulate multiple mitotic 
checkpoints (Lens, Vader et al. 2006), and ultimately contribute to genetic instability and 
aneuploidy, in vivo.  Second, this pathway may directly promote drug and radiation 
resistance.  Higher survivin levels have been consistently linked to inhibition of apoptosis 
induced by DNA damaging agents (Ghosh, Dohi et al. 2006), as well taxanes (O'Connor, 
Wall et al. 2002), two mainstay therapeutic regimens in breast cancer.  Third, survivin 
may operate as a Notch-regulated cytoprotective and/or mitotic factor to promote long-
term persistence of breast cancer “stem cells” (Liu, Dontu et al. 2005; Buono, Robinson 
et al. 2006), potentially contributing to ductal carcinoma in situ (Farnie, Clarke et al. 
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2007), an idea consistent with the presence of survivin in “stemness” gene signatures 
(Taubert, Wurl et al. 2007), and its role in hematopoietic stem cell viability (Leung, Xu et 
al. 2007). 
Although the introduction of “targeted” therapies (Hudis 2007), including anti-
hormonal strategies (Jordan 2007), has significantly improved the survival of breast 
cancer patients, the prognosis of metastatic disease remains grim.  This often involves 
ER- subsets of the disease, for instance triple-negative (ER, PR and HER-2), basal-like 
breast cancer, which is characterized by high recurrence rates (Sotiriou and Piccart 2007).  
Here, the increased sensitivity of ER- versus ER+ breast cancer cells to therapeutic Notch 
inhibition, in vitro and in preclinical models, suggests that these cells may become 
dependent, or “addicted” (Weinstein and Joe 2006) to Notch signaling.  Although the 
importance of “oncogene addiction” in long-term maintenance of the neoplastic 
phenotype, in vivo, is debated, the notable clinical responses observed in subsets of 
cancer patients after targeting of specific cellular pathways support their pivotal role(s) as 
disease “drivers” (Sharma, Bell et al. 2007).  A similar paradigm has been proposed for 
Notch (Roy, Pear et al. 2007), and GSIs have been pursued as therapy for potential 
“Notch-addicted” tumors, especially T-cell leukemia (Shih Ie and Wang 2007).  Despite 
its rationale, this approach has not been without concerns.  GSIs are not entirely specific 
for Notch, as they also affect other transmembrane proteins, including E-cadherin, EGFR 
and CD44 (Fortini 2002), and global inhibition of Notch receptors has been associated 
with serious toxicity, especially aberrant differentiation of intestinal epithelium, and T-
cell development, in vivo (Wong, Manfra et al. 2004).  The data presented here suggest a 
more encouraging scenario, as a prototype peptidyl GSI was safely administered 
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systemically to mice with effective anticancer activity, with negligible systemic or organ 
toxicity.  Although this bodes well for potential further (pre)clinical development of 
similar compounds, it remains to be seen whether long-term GSI treatment will 
eventually result in pharmacologic resistance, as observed in leukemia (Weng, Ferrando 
et al. 2004). 
In summary, we have uncovered a novel Notch-survivin signaling axis, 
preferentially exploited in ER- breast cancer cells.  Although this pathway may contribute 
to worse clinical outcome, a potential “addiction” of ER- breast cancer cells to a Notch-
survivin axis may open new prospects for individualized therapy of these recurrence-
prone patients. 
Material and Methods 
Cell lines and viral transductions 
Breast adenocarcinoma cell lines MCF-7, MDA-MB-231, and cervical carcinoma 
HeLa cells were obtained from the American Type Culture Collection (ATCC, Manassas, 
VA), and maintained in culture as recommended by the supplier.  Breast adenocarcinoma 
cell lines T47D, Sum149, and HBL100 were generously provided by Dr. Arthur M. 
Mercurio (University of Massachusetts Medical School).  Primary human mammary 
epithelial cells (HMEC) were obtained from Lonza, Allendale, NJ.  Primary human 
foreskin fibroblasts (HFF), human gingival fibroblasts (HGF), human epithelial 
fibroblasts (WS-1), and human intestinal epithelial cells (INT) (all from ATCC) were 
cultured per manufacturer’s instructions, and used at early passages before the onset of 
senescence.  A NIC construct has been characterized previously (Small, Kovalenko et al. 
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2001).  For adenoviral transduction, various cell types (1x105) were incubated with 
replication-defective adenovirus pAd-NIC, pAd-GFP, or pAd-Control at multiplicity of 
infection of 50 for 4-8 h at 37°C, harvested at increasing time intervals, and processed for 
individual experiments. 
Semi-quantitative RT-PCR 
Total RNA was harvested using the RNeasy Kit (Qiagen, Valencia, CA).  One µg 
of total RNA was reversed transcribed in the presence of SuperScript II polymerase plus 
random primer (Invitrogen, Carlsbad, CA).  Survivin or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) cDNA was amplified (28 cycles), and separated on 1.5% 
agarose gels.  Band intensity normalized to GAPDH expression was quantified using 
Labworks 4.6 (UVP BioImaging Systems, Upland, CA). 
Western blotting and antibodies   
Cellular extracts were prepared in a lysis buffer containing 20 mM Tris pH 7.5, 
0.5% DOC, 1% Triton, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 1 mM 
Na3VO4, plus protease inhibitors (Roche Applied Science, Indianapolis, IN).  Lysates 
were separated by SDS gel electrophoresis, and transferred to Immobilon membranes 
(Millipore, Billerica, MA).  The following antibodies were used: survivin (1:1000) from 
NOVUS Biologicals, Littleton, CO), XIAP (1:500), GFP (1:500), cytochrome c (1:1000), 
and Cox-4 (1:5000) from BD Biosciences (San Jose, CA), Bcl-2 (1:500) from Santa Cruz 
Biotechnology (Santa Cruz, CA), V5 epitope for detection of NIC or Jagged-1 (1:5000) 
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from Invitrogen, NIC (1:1000) from Rockland (Gilbertsville, PA), and β-actin (1:5000) 
from Sigma (St. Louis, MO). 
Analysis of survivin gene expression 
A cDNA construct comprising the first 830 bp of the mouse survivin promoter 
upstream of the translational initiation codon fused to GFP (ms-830-GFP) was 
characterized previously (Xia and Altieri 2006).  HeLa cells were co-transfected with ms-
830-GFP plus Notch-1 or Jagged-1 cDNA by Lipofectamine.  After 24 h, cells were 
analyzed for GFP expression by Western blotting, or fluorescence microscopy with 
image acquisition on an Olympus IX71 microscope outfitted with an Olympus Regina 
camera (Center Valley, PA).  A putative RBP-Jκ binding site at position -355 in ms-830-
GFP was mutated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA) with primer: 5’-
GAACCTGCAGAGCACATGttACTTGCAGCGGACATGC-3’.  The mutant construct 
(mutant ms-830-GFP) was confirmed by DNA sequencing, transfected in HeLa cells, and 
analyzed for GFP expression after Notch stimulation.  For electrophoretic mobility shift 
assay (EMSA), MDA-MB-231 nuclear extracts were prepared using the CelLytic 
NuCLEAR extraction kit (Sigma) according to the manufacturer’s instructions.  cDNA 
sequences corresponding to the -355 region of ms-830-GFP (5’-GGAAGAACCTGCAG-
AGCACATGGGACTTGCAGCGGACATGCT-3’), a random survivin promoter region 
(5’-TGCAACGCCAACCTGGGCTGTGTTCGGGGCATGCCCAGCCTG-3’), or an 
RBP-Jκ binding region in the human Hes promoter (5’-GTTACTGTGGGAAAGAAAG-
TC-3’) were synthesized.  Probes (3.5 pmol) were made double-stranded by annealing at 
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equimolar concentrations, and 5’ end-labeled with 1 µl of [γ32P]ATP (3000 Ci/mmol) and 
10 U of T4 polynucleotide kinase (NEB, Ipswich, MA) for 10 min at 37°C.  MDA-MB-
231 nuclear extracts were incubated with the reaction mixture (10 µl) containing 
radiolabeled DNA probes, 2 µg of poly(dI-dC) (Sigma), 10 mM Tris (pH 7.5), 1 mM 
MgCl2, 50 mM NaCl, 4% glycerol, 0.5 mM EDTA, 0.5 mM DTT, 50 µg BSA, and 
various unlabeled competing oligonucleotides.  After 30 min incubation at 22°C, samples 
were separated by electrophoresis on 4% non-denaturing polyacrylamide gels, and bands 
were visualized by autoradiography. 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed using the ChIP-IT Express 
Kit (Active Motif, Carlsbad, CA) per the manufacturer’s protocols.  MDA-MB-231 cells 
were infected with pAd-NIC prior to fixation with 1% formaldehyde for 10 min.  Cells 
were washed, lysed, and sonicated to reduce DNA lengths to a range of 300–600 bp.  The 
chromatin/DNA complexes were incubated with antibodies to RNA Pol II (Active Motif), 
RBP-Jκ (Santa Cruz Biotechnology), or IgG (Active Motif) for 18 h at 4°C.  The immune 
complexes were precipitated, eluted, reverse cross-linked and treated with proteinase K.  
The resulting DNA samples were amplified with primers to the RNA Polymerase II site 
in the GAPDH promoter (forward, 5’ TACTAGCGGTTTTACGGGCG 3’; reverse, 5’ 
TCGAACAGGAGGAGCAGAGAGCGA 3’), the -305 bp putative RBP-Jκ binding site 
in the human survivin promoter (forward, 5’ ACCACGCCCAGCTAATTTTTG 3’; 
reverse, 5’ CCTCGACTGCTTTCAAAGAACG 3’), and the RBP-Jκ binding site in the 
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Hes promoter (forward, 5’ CGTGTCTCCTCCTCCCATTG 3’; reverse, 5’ CCAGGACC-
AAGGAGAGAGGT 3’). 
Cell cycle analysis  
Cells (1.5x105) were synchronized at the G1/S transition by treatment with 2 mM 
thymidine for 18 h at 37°C.  In some experiments, cells were released after 18 h, infected 
with pAd-NIC or pAd-GFP for 8 h, and resynchronized with 1 mM thymidine for another 
18 h.  Aliquots of synchronized cultures were collected at 0, 4, 8, 10, 12, 14 h after the 
second thymidine release, and analyzed for DNA content by propidium iodide staining 
and flow cytometry, or alternatively, by Western blotting.  For single-color cell cycle 
analysis, cells were fixed in 70% ethanol for 18 h at -20°C, and analyzed by flow 
cytometry.  Cell cycle populations were gated, and quantified using FlowJo software 
(TreeStar, Ashland, OR).  A pAd-T34A survivin dominant negative mutant was 
characterized previously (Mesri, Wall et al. 2001).  In some experiments, MDA-MB-231 
cells were infected with the combinations pAd-NIC/pAd-Control, pAd-T34A/pAd-
Control, or pAd-NIC/pAd-T34A, for 24 h, synchronized with 2 mM thymidine for 24 h, 
and released into S-phase.  Cultures were collected after various time intervals, and 
analyzed for DNA content by propidium iodide staining, or, alternatively, by Western 
blotting. 
Cell death assays  
A γ-secretase inhibitor (GSI) z-Leu-Leu-Nle-CHO was purchased from 
Calbiochem (San Diego, CA), and dissolved in DMSO.  In metabolic activity assays, 
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cells were treated with GSI or DMSO for 24 h, incubated with 50 µg/ml MTT for 2 h, 
and analyzed at A595.  In other experiments, cells treated with GSI or DMSO were spun 
onto slides, DNA was stained with DAPI, and cells with chromatin 
condensation/fragmentation were scored by fluorescence microscopy.  For experiments 
of cytochrome c release, GSI-treated cells were harvested, fractionated into cytosolic 
extracts using the ApoAlert Cell Fractionation Kit (Clontech, Mountain View, CA), and 
analyzed for time-dependent release of cytochrome c, by Western blotting.  Caspase 
activity was determined using the Capase-3/7 In Situ Assay Kit (Millipore) by 
multiparametric flow cytometry, in the presence or absence of a broad spectrum caspase 
inhibitor zVAD-fmk (American Peptides, Sunnyvale, CA, 20 μM). 
Analysis of tumorigenesis 
For soft agar colony formation, 1x104 cells were treated with GSI (0.125–10 μM) 
for 24 h, suspended in 2 ml of DMEM/0.35% bactoagar, and plated onto 6-well tissue 
culture plates containing 2 ml DMEM/0.75% bactoagar as a bottom layer.  After a 2-
week incubation at 37°C, 5% CO2, colonies were stained with 0.005% crystal violet and 
counted under high-power field.  All experiments involving animals were approved by an 
Institutional Animal Care and Use Committee.  For xenograft tumor studies, 5x106 
MDA-MB-231 cells were injected into each flank of 6- to 8-week-old female CB17 
SCID/beige mice (Taconic, Hudson, NY).  When tumors reached 150-175 mm3 in 
volume, mice were randomized (3 animals/group, 6 tumors/group, 2 independent 
experiments) and treated daily with intraperitoneal (i.p.) injections of 3 mg/kg GSI or 
vehicle control.  For experiments in vivo, z-Leu-Leu-Nle-CHO (American Peptides) was 
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synthesized to >99% purity, and dissolved in 25% Cremophor/PBS (Sigma).  Mice were 
weighed daily, monitored for signs of pain and distress, and tumor sized measured in 
three dimensions with a caliper using the equation LxW2/2 (mm3).  All animals were 
euthanized when tumor volume exceeded 1500 mm3.  At the end of the experiment, liver, 
spleen, lung, kidney, pancreas, and colon were harvested, fixed in formalin, and 
embedded in paraffin blocks for histology.  For quantification of lung micrometastases, 
serial lung sections were cut 20 µm apart, stained with hematoxylin-eosin, and analyzed 
by light microscopy. 
Statistical Analysis 
Data were analyzed using the unpaired t-test on a GraphPad software program 
(Prism 4.0).  All statistical tests were two sided.  A p value of 0.05 was considered to be 
statistically significant. 
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Figure 3-1.  Regulation of survivin expression by Notch.  
A.  Semi-quantitative RT-PCR.  A panel of ER- (MDA-MB-231, HBL100, Sum149), 
ER+ (MCF-7, T47D), or primary human mammary epithelial cells (HMEC) were 
transduced with pAd-NIC or pAd-Control, and assayed for survivin mRNA levels.  B.  
Western blotting.  Transduced MDA-MB-231 or MCF-7 cells were harvested at the 
indicated time intervals, and analyzed by Western blotting.  C.  Analysis of normal cells.  
Transduced primary HMEC were analyzed by Western blotting at the indicated time 
intervals. *, nonspecific.  Numbers at the bottom of each panel correspond to normalized 
densitometric quantification of survivin protein bands. 
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Figure 3-2.  Notch regulation of survivin gene expression. 
A.  Maps of survivin promoter constructs (ms-830-GFP) and mutant survivin promoter 
construct (mutant ms-830-GFP).  Two putative RBP-Jκ sites at -355 and -543 are 
indicated.  B.  Fluorescence microscopy (left panels).  HeLa cells co-transfected with 
wild type ms-830-GFP plus pcDNA3, Notch-1, or Jagged-1 were analyzed by 
fluorescence microscopy (left panels).  GFP expression was confirmed by Western 
blotting (right panel).  C.  Mutant ms-830-GFP co-transfections.  Cells co-transfected 
with wild type or mutant ms-830-GFP plus pcDNA3 or Notch-1 were quantified for 
GFP-positive cells.  Mean±SEM (n=10 high-power fields with approximately 200 
cells/field) from two independent experiments.  ***, p<0.0001.  D.  EMSA.  Nuclear 
extracts from MDA-MB-231 cells were incubated with 32P-γ ATP-labeled probe 
duplicating the survivin RBP-Jκ site at -355 (left panel), in the presence or absence of 
unlabeled competitors.  An RBP-Jκ probe from the Hes promoter was used as a control 
(right panel).  Arrow, position of a DNA-protein complex. 
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Figure 3-3.  Chromatin immunoprecipitation of the human survivin promoter.   
A.  Map of the human survivin promoter.  Putative RBP-Jκ site at -305 in the human 
survivin gene is indicated.  B.  ChIP assay.  Chromatin from MDA-MB-231 cells 
transduced with pAd-NIC was incubated with antibodies to RNA polymerase II (RNA 
Pol II), RBP-Jκ, or IgG, and the immunoprecipitated DNA was amplified with primers 
for the putative RBP-Jκ site in the human survivin promoter at -305, the RBP-Jκ site in 
the Hes promoter, or a non-specific promoter region. 
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Figure 3-4.  Effect of activated Notch-1 on cell cycle progression.   
A.  Thymidine synchronization.  Transduced MDA-MB-231 cells were synchronized 
with 2 mM thymidine, and analyzed by Western blotting at the indicated time intervals 
after release.  B.  Cell cycle analysis.  Synchronized and transduced MDA-MB-231 cells 
were analyzed for DNA content by propidium iodide staining and flow cytometry at the 
indicated time intervals.  The percentage of cells in each cell cycle phase is indicated.  C.  
Cell proliferation.  Transduced MDA-MB-231 or MCF-7 cells were counted at the 
indicated time intervals, starting at d. 1 (arrow).  Mean±SEM (n=3).  D.  Rescue from 
mitotic cell death.  MDA-MB-231 cells were transduced with combinations of pAd-NIC, 
pAd-Control, and pAd-T34A, synchronized, and analyzed for DNA content by propidium 
iodide staining and flow cytometry.  The percentage of cells in each cell cycle phase is 
indicated. 
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Figure 3-5.  Effect of Notch inhibition on breast cancer cell viability.   
A.  Western blotting.  The indicated breast cancer or normal cell types were treated with 
DMSO (-) or 2 µM GSI (+), harvested after 24 h, and analyzed by Western blotting.  B.  
NIC rescue of GSI-induced cell death.  Transduced MDA-MB-231 (top panels) or MCF-
7 (bottom panels) cells were treated with 1 µM GSI or DMSO for 24 h, and analyzed for 
apoptosis by DEVDase activity.  The percentage of cells in each quadrant is indicated.  C.  
Cell viability.  The indicated breast cancer (left and middle panels), or normal (right 
panel) cell types were treated with increasing concentrations of GSI (0.125–10 µM) for 
24 h, and analyzed for cell viability by MTT.  Mean±SEM (n=4).  IC50 values for GSI-
induced cell killing are as follows: MDA-MB-231, 1.196 µM; HBL100, 3.416 µM; 
Sum149, 2.030 µM; MCF-7, >10 µM; T47D, 5.709 µM; normal cell lines, >10 µM. 
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Figure 3-6.  Induction of apoptosis by Notch inhibition.   
A.  Cell death.  MCF-7 or MDA-MB-231 cells were treated with GSI (2.5 µM), harvested 
after 24 h, and analyzed for nuclear morphology of apoptosis by DAPI staining and 
fluorescence microscopy.  Left panel, mean±SEM of 5-10 fields with an average of 60-30 
cells/field).  Right panel, release of mitochondrial cytochrome c in the cytosol by 
Western blotting.  Bottom right panel, normalized densitometric quantification of 
cytochrome c protein bands.  Cox-4 was used as a control mitochondrial marker.  B.  
Caspase requirement.  MDA-MB-231 cells were treated with 5 µM GSI or 1 µM STS, 
and analyzed for DEVDase activity after 24 h, in the presence or absence of zVAD.  
Percentage of cells in each quadrant is indicated.  C.  Survivin rescue.  Transduced MDA-
MB-231 cells were treated with 1 µM GSI for 24 h, and analyzed for DNA content.  The 
percentage of cells with hypodiploid (sub-G1) DNA content is indicated.  D.  Colony 
formation assay.  MCF-7 or MDA-MB-231 cells were treated with increasing 
concentrations of GSI (0.125–20 µM) for 24 h, plated onto semisolid medium.  After 2 
weeks, colonies (left panels) were stained with 0.005% crystal violet, and quantified by 
light microscopy (right panel).  Mean±SEM (n=3).  Six fields/GSI concentration were 
quantified per condition (right panel). 
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Figure 3-7.  Anti-cancer activity of Notch inhibition.   
A.  Kinetics of tumor growth.  CB17 SCID/beige mice were injected subcutaneously with 
5x106 MDA-MB-231 cells into each flank.  When tumors reached 150-175 mm3, mice 
(3 animals/group, 6 tumors/group) were treated with 3 mg/kg GSI daily or vehicle as i.p. 
injections.  Arrow, start of GSI treatment.  Mean±SEM of tumor volume at each 
indicated time point.  B.  Effect of Notch inhibition on lung metastases.  Lung sections 
from vehicle- or GSI-treated animals were analyzed by hematoxylin-eosin staining (left 
panel), and lung micrometastases were quantified in serial tissue sections (20 µm apart) 
by light microscopy (right panel; mean±SEM from 5 independent fields. **, p<0.0001).  
Magnifications, left panels, 10x; right panels, 40x.  C.  Tissue histology.  The indicated 
organs were collected from mice treated with vehicle (untreated) or GSI at the end of the 
experiment (14 d), paraffin-embedded, and analyzed by hematoxylin-eosin staining. 
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SUPPLEMENTAL FIGURES 
 
 
 
 
 
 
Supplemental Figure 3-8.  Semi-quantitative Western blotting of Notch activation.   
A.  MDA-MB-231 and MCF-7 cells were infected with pAd-NIC or pAd-Control and 
harvested after 24-72 h.  B.  Densitometric analysis. 
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Supplemental Figure 3-9.  Effect of second GSI.  
MDA-MB-231 breast cancer cells were treated with 10 µM or 15 µM of z-Ile-Leu-CHO 
or control vehicle (DMSO) for the indicated time intervals, and analyzed by Western 
blotting. 
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Supplemental Figure 3-10.  Effect of GSI on tumor cell viability.  
The indicated tumor cell types were incubated with increasing concentrations of GSI, 
harvested after 24 h and analyzed for cell viability by an MTT assay. Mean±SEM (n=3). 
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Supplemental Figure 3-11.  Rescue of colony formation by survivin after GSI. 
MDA-MB-231 cells were infected with pAd-survivin or pAd-Control and subsequently 
treated with low dosage GSI for 24 h.  After two weeks, cells were stained with crystal 
violet and counted.  Mean±SEM (n=6);  *, p=0.004; **, p=0.29   
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Supplemental Figure 3-12.  Animal body weight during GSI treatment.   
Mice treated with vehicle (untreated) or 3 mg/kg GSI i.p. daily were weighted throughout 
the course of the experiment.  Arrow, start of GSI treatment.  Mean±SEM (n=6).   
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Chapter 4. Identification of novel IGF-1/survivin regulatory 
mechanism in prostate cancer 
Valentina Vaira, Connie W. Lee, Hira L. Goel, Silvano Bosari,  
Lucia R. Languino, and Dario C. Altieri 
This chapter represents Valentina Vaira’s thesis work on IGF-1 signaling in 
prostate cancer to which I contributed after she returned to Italy.  The text is a version of 
the manuscript published online in Oncogene on October 30, 2006 (Vaira, Lee et al. 
2007).  I verified the induction of survivin by IGF-1 signaling, analyzed the cell cycle 
modulation of IGF-1 on prostate cancer cells, and determined the contribution of 
mTOR/survivin signaling to prostate cancer cell viability.  Valentina Vaira and Dario 
Altieri wrote the text while I contributed to the material and methods section and 
provided feedback on the text.   
Abstract 
Survivin is a dual regulator of cell proliferation and cell viability over-expressed 
in most human tumors.  Although strategies to lower survivin levels have been pursued 
for rational cancer therapy, the molecular circuitries controlling survivin expression in 
tumors have not been completely elucidated.  Here, we show that stimulation with Type 1 
Insulin-like Growth Factor (IGF-1) results in increased survivin expression in prostate 
cancer cells.  This response is independent of de novo gene transcription, changes in 
mRNA expression, or modifications of survivin protein stability.  Instead, IGF-1 induced 
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persistence and translation of a pool of survivin mRNA, in a reaction abolished by the 
mTOR (mammalian Target Of Rapamycin) inhibitor, rapamycin.  Forced expression of 
the mTOR target p70S6K1 reproduced the increase in survivin expression in prostate 
cancer cells, whereas acute ablation of endogenous p70S6K1 by small interfering RNA 
downregulated survivin levels.  Rapamycin, alone or in combination with suboptimal 
concentrations of taxol reduced survivin protein levels, and decreased viability of prostate 
cancer cells.  Therefore, IGF-1/mTOR signaling elevates survivin in prostate cancer cells 
via rapid changes in mRNA translation.  Antagonists of this pathway may be beneficial to 
lower an anti-apoptotic threshold maintained by survivin in prostate cancer. 
Introduction 
Deregulation of apoptosis leading to aberrantly increased cell survival is a 
hallmark of cancer (Hanahan and Weinberg 2000), and may result from increased 
expression of cell death antagonists or loss of cell death inducers (Hengartner 2000).  
Restoration of apoptotic pathways is being explored for rational cancer therapy (Reed 
2003), and targeting survival proteins of the Bcl-2 (Cory and Adams 2002), or Inhibitor 
of Apoptosis (IAP) (Salvesen and Duckett 2002) gene family has been associated with 
tumor cell death, and in some cases, promising clinical responses (Reed 2003).  Survivin 
(Ambrosini, Adida et al. 1997) has attracted attention as a unique IAP member (Salvesen 
and Duckett 2002) for its differential expression in tumors as opposed to normal tissues 
(Ambrosini, Adida et al. 1997), and a role in multiple pathways of tumor cell 
maintenance, including protection from apoptosis, cell division, the cellular stress 
response, and p53-dependent checkpoints (Altieri 2003). 
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Although the differential expression of survivin in tumors is influenced 
transcriptionally by oncogenic signaling (Altieri 2003), and loss of p53-mediated gene 
repression (Hoffman, Biade et al. 2002; Mirza, McGuirk et al. 2002), other, non-
transcriptional regulatory mechanisms have been identified.  These include rapid changes 
in survivin protein stability modulated by phosphorylation (O'Connor, Grossman et al. 
2000), subcellular trafficking controlled by monoubiquitination (Vong, Cao et al. 2005), 
and dynamic exchange of survivin pools among individual subcellular compartments 
(Dohi, Beltrami et al. 2004).  In prostate cancer, a plethora of molecular pathways has 
been associated with modulation of survivin levels, including extracellular matrix-
integrin interactions (Fornaro, Plescia et al. 2003), antiandrogen therapy (Zhang, Latham 
et al. 2005), STAT3 activation (Nam, Buettner et al. 2005), and Smad/BMP-7 signaling 
(Yang, Lim et al. 2006), thus contributing to apoptosis resistance.  In addition, activation 
of PI3 kinase/Akt signaling, which is a common hallmark of prostate cancer, has been 
consistently linked to increased survivin levels (Dan, Jiang et al. 2004), but the 
downstream target(s) of this response have not been identified. 
Here, we studied a potential link between survivin expression and the mammalian 
Target of Rapamycin (mTOR) (Wullschleger, Loewith et al. 2006), a downstream 
effector of Akt with critical roles in cell growth, cell survival and adaptation to stress 
(Hay 2005). 
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Results 
IGF-1 increases survivin protein expression in prostate cancer cells 
Serum-deprived prostate adenocarcinoma DU145 cells exhibited low expression 
of endogenous survivin, which was induced by IGF-1 in a concentration-dependent 
manner, by immunoblotting (Figure 4-1A).  IGF-1 induction of survivin was detectable 
as early as 12 h after stimulation (Figure 4-1A), and persisted throughout a 24 h (Figure 
4-1B) or 48 h (Figure 4-1C) time interval.  In contrast, mitogen stimulation of DU145 
cells with FBS did not modulate survivin levels after 12 h (Figure 4-1A), but increased 
survivin expression at 24 and 48 h after treatment (Figure 4-1B and C).  The effect of 
IGF-1 was specific for survivin, as FBS or IGF-1 did not modulate the expression of 
another IAP member, XIAP, or β-actin (Figure 4-1C).  Finally, IGF-1 stimulation did not 
significantly affect the DNA content profile of DU145 cells at comparable time intervals 
(Figure 4-1D), suggesting that changes in survivin expression after exposure to IGF-1 
were independent of cell cycle progression. 
IGF-I receptor (IGF-1R) modulates survivin expression.   
To determine the signaling requirements of IGF-1 modulation of survivin, we 
used MEF derived from IGF-1R null mice, which were stably transfected with WT or 
mutant IGF-1R (Romano, Prisco et al. 1999).  Stimulation with IGF-1 resulted in 
increased survivin expression only in cells expressing WT IGF-1R (Figure 4-2A).  In 
contrast, IGF-1 stimulation of cells expressing mutant receptor GR35 or GR48 did not 
modulate endogenous survivin levels (Figure 4-2A).  In addition, IGF-1 stimulation of 
cells expressing WT IGF-1R resulted in strong receptor tyrosine phosphorylation (Figure 
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4-2B).  In contrast, tyrosine phosphorylation was detected in GR35 cells, but completely 
absent in GR48 cells, and no receptor phosphorylation was observed without IGF-1 
(Figure 4-2B).  In addition, cells transfected with WT IGF-1R exhibited a transformed 
phenotype as judged by colony formation in soft agar, whereas expression of mutant 
receptor GR35 or GR48 did not result in colony formation (Figure 4-2C). 
IGF-1 induction of survivin independent of transcription or protein 
stabilization 
To investigate the mechanism(s) of IGF-1 induction of survivin, we first analyzed 
potential changes in survivin mRNA levels in untreated or stimulated cultures, by semi-
quantitative PCR.  In control experiments, addition of FBS to serum-deprived DU145 
cells resulted in increased survivin mRNA expression (Figure 4-3A).  In contrast, IGF-1 
stimulation did not significantly increase survivin mRNA levels, as compared with 
untreated cultures (Figure 4-3A).  We then transfected cells with survivin promoter-
luciferase constructs pLuc-441 and pLuc-1430 encompassing most of the known 
transcriptional requirements for survivin gene expression.  FBS stimulation of serum-
deprived DU145 cells resulted in a 4- to 6-fold increased in β-galactosidase-normalized 
luciferase activity of both pLuc-441 and pLuc-1430 (Figure 4-3B), consistent with 
previous observations (Li and Altieri 1999).  In contrast, concentrations of IGF-1 that 
maximally increased survivin protein levels did not significantly enhance the 
transcriptional activity of either survivin promoter, as compared with control cultures 
(Figure 4-3B).  We next asked whether IGF-1 stimulation affected survivin protein 
stability.  Exposure of serum-deprived DU145 cells to cycloheximide resulted in rapid 
disappearance of survivin levels, detected as early as 2 h after addition and throughout a 
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6-h time interval (Figure 4-3C).  Although serum stimulation partially restored survivin 
levels in the presence of cycloheximide, treatment with IGF-1 had no effect (Figure 
4-3C).  In control experiments, IGF-1 did not affect XIAP expression in the presence or 
absence of cycloheximide (Figure 4-3C). 
IGF-1 triggers survivin mRNA accumulation and translation 
We next asked whether downstream inhibition of IGF-1 signaling by rapamycin 
affected survivin expression.  Stimulation of serum-deprived DU145 cells with IGF-1 or 
FBS strongly increased survivin expression (Figure 4-4A), in agreement with the data 
presented above.  Treatment of DU145 cells with rapamycin nearly completely abolished 
IGF-1 induction of survivin, whereas FBS stimulation of survivin was not significantly 
affected (Figure 4-4B).  No modulation of XIAP was observed after IGF-1 or FBS 
stimulation, with or without rapamycin (Figure 4-4B), and no decrease in cell viability 
was observed at the concentrations of rapamycin used (Figure 4-6A, left panel). 
Next, we treated IGF-1 or FBS-stimulated DU145 cells with the transcriptional 
inhibitor actinomycin D, and analyzed changes in survivin mRNA levels, with or without 
rapamycin.  In these experiments, IGF-1 stimulation was associated with persistence of 
survivin mRNA levels over an 8-h time interval, in a reaction completely abolished by 
rapamycin (Figure 4-4C).  In contrast, FBS treatment did not preserve survivin mRNA 
levels in the presence of actinomycin D (Figure 4-4C).  Preservation of survivin mRNA 
levels in a rapamycin-sensitive response was also observed after treatment with an 
unrelated transcriptional inhibitor, DRB (Figure 4-4D), thus ruling out that the observed 
effect was due to non-specific activation of a cellular stress response. 
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Requirement of p70S6K in IGF-1 regulation of survivin   
Next, we wanted to identify the molecular requirements of rapamycin-sensitive 
modulation of survivin.  We transfected DU145 cells with cDNA encoding WT or 
rapamycin-insensitive p70S6K, a downstream substrate of mTOR.  Expression of WT 
p70S6K substituted for IGF-1 stimulation in inducing survivin expression in serum-
deprived DU145 cells (Figure 4-5A).  Treatment of transfected DU145 cells with 
rapamycin partially reduced the extent of survivin induction by p70S6K (Figure 4-5A).  
Conversely, transfection of serum-deprived DU145 cells with rapamycin-insensitive 
p70S6K (T389E∆CT) resulted in strong upregulation of survivin in the absence of IGF-1, 
in a reaction unaffected by rapamycin (Figure 4-5B).  In control experiments, FBS 
induction of survivin was unaffected by WT or rapamycin-insensitive p70S6K in the 
presence or absence of rapamycin (Figure 4-5A, B).  Next, we ablated p70S6K by 
siRNA, and analyzed changes in survivin expression with or without IGF-1 stimulation.  
Serum-deprived DU145 cells transfected with control siRNA exhibited increased 
survivin expression after IGF-1 stimulation, as compared with untreated cultures (Figure 
4-5C).  In contrast, acute knockdown of p70S6K by siRNA completely abolished IGF-1-
mediated increased survivin expression (Figure 4-5C).  Conversely, siRNA knockdown 
of p70S6K did not affect FBS induction of survivin in DU145 cells (not shown). 
Inhibition of mTOR sensitizes prostate cancer cells to combination therapy 
To determine the impact of IGF-1 induction of survivin in prostate cancer cells, 
we treated DU145 cells with rapamycin, and investigated changes in cell viability.  
Exposure of serum-deprived DU145 cells to rapamycin did not induce loss of cell 
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viability for the first 24 h (Figure 4-6A).  However, a 48 h treatment of DU145 cells with 
rapamycin resulted in ~50% decrease in cell viability, in a reaction fully reversed by IGF-
1 stimulation, whereas FBS stimulation was ineffective (Figure 4-6B).  Second, we 
combined rapamycin with established cytotoxic agents and investigated changes in 
survivin expression and cell viability.  Treatment of DU145 cells with the combination of 
rapamycin plus a suboptimal concentration of taxol for 24 h resulted in nearly complete 
disappearance of survivin expression, as compared with either treatment alone (Figure 
4-6B).  In contrast, the combination of doxorubicin plus rapamycin was ineffective (not 
shown).  IGF-1 stimulation of DU145 cells treated with the combination of taxol plus 
rapamycin failed to restore survivin expression, whereas FBS increased survivin levels to 
approximately 50% of those of untreated cultures (Figure 4-6B).  Consistent with a 
critical reduction in the anti-apoptotic threshold maintained by survivin, the taxol plus 
rapamycin combination was more effective than either treatment alone in reducing 
DU145 cell viability in the presence of IGF-1 (Figure 4-6C). 
Discussion 
In this study, we have shown that IGF-1 stimulation of prostate cancer cells 
results in increased survivin expression, and that this pathway is mediated by stabilization 
and translation of a pool of survivin mRNA.  Inhibition of mTOR (Wullschleger, 
Loewith et al. 2006) with rapamycin, alone or in combination with taxol, or molecular or 
genetic interference with its downstream target, p70S6K (Wullschleger, Loewith et al. 
2006), abolished survivin increase by IGF-1, and decreased prostate cancer cell viability. 
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Because of its “crossroad” role in multiple essential pathways of tumor cell 
maintenance, and its differential expression in cancer as opposed to normal tissues, 
survivin is being actively pursued as a novel target for rational cancer therapy (Altieri 
2003).  A validating principle of this approach is that lowering intracellular survivin 
levels below a critical threshold using a variety of approaches, including antisense, 
dominant negative mutants, or siRNA sequences, has been consistently associated with 
arrest of cell proliferation, spontaneous apoptosis and sensitization to cell death stimuli, 
including cytotoxics and ionizing radiation (Altieri 2006).  In this context, much attention 
has been devoted towards elucidating the molecular requirements of survivin gene 
transcription, but recent evidence points to additional, non-transcriptional mechanisms 
controlling survivin levels in tumor cells (Altieri 2003).  One such pathway is centered on 
IGF-1 ligation to its cognate membrane receptor that has been shown to increase survivin 
expression in prostate (Zhang, Latham et al. 2005), myeloma (Stromberg, Ekman et al. 
2006) and liver (Hopfner, Huether et al. 2006) tumor cell types, even though the 
underlying mechanism(s) of this response had remained elusive.  As now reported here, 
this pathway depends on IGF-1R transforming potential (Sell, Dumenil et al. 1994), does 
not involve changes in cell cycle distribution, and is not associated with de novo survivin 
promoter activity or increased survivin protein stability.  Conversely, IGF-1 modulates 
survivin levels by favoring stabilization and translation of a survivin mRNA pool through 
activation of the mTOR pathway. 
Regulation of survivin expression has been linked in multiple experimental 
systems to increased Akt activity, a Ser/Thr kinase downstream of PI3 kinase signaling 
(Amaravadi and Thompson 2005).  This is relevant for prostate cancer, where survivin is 
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highly expressed (Fornaro, Plescia et al. 2003; Krajewska, Krajewski et al. 2003), and 
Akt activity is commonly deregulated after loss of the inhibitory lipid phosphatase, PTEN 
(Majumder and Sellers 2005).  In turn, increased Akt activity provides a broad anti-
apoptotic environment through cytoplasmic trapping of cell death mediators (Datta, 
Dudek et al. 1997; Goswami, Burikhanov et al. 2005), modulation of NF-κB (Kane, 
Shapiro et al. 1999; Kane, Mollenauer et al. 2002), and repression of apoptotic inducers 
(Brunet, Bonni et al. 1999).  In addition, Akt phosphorylates and inactivates the tuberous 
sclerosis complex, TSC2, a negative regulator of mTOR signaling (Wullschleger, 
Loewith et al. 2006).  The data presented here identify a novel survival circuitry initiated 
by IGF-1/Akt signaling, and involving mTOR activation, p70S6K activation, and 
increased stability/translation of a survivin mRNA pool.  This pathway is specific for 
IGF-1, as serum mitogens upregulated survivin in tumor cells independently of mTOR or 
p70S6K, and is centered on survivin, as XIAP (Salvesen and Duckett 2002), a IAP 
member whose levels are controlled by protein translation (Holcik, Yeh et al. 2000), was 
not affected. 
The mTOR pathway constitutes a “sensor” network for environmental nutrients or 
stress conditions, thus affecting cell growth (cell volume), cellular proliferation, and 
activation of metabolic rescue pathways, i.e. autophagy (Wullschleger, Loewith et al. 
2006).  As a multifaceted mTOR effector, survivin appears ideally positioned to 
contribute to these responses, by favoring mitotic progression, resistance to apoptosis, 
and increased cellular adaptation to stress (Altieri 2003).  Conversely, targeted inhibition 
of IGF-1/Akt/mTOR couples to cell cycle arrest and induction of apoptosis, which may 
be contributed by acute loss of survivin levels (Decker, Hipp et al. 2003; Hopfner, 
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Huether et al. 2006; Stromberg, Ekman et al. 2006), Forkhead-mediated transcription of 
the cyclin-dependent kinase inhibitor p27 (Wullschleger, Loewith et al. 2006), and 
activation of p53-dependent apoptosis (Levine, Feng et al. 2006). 
In summary, these data reinforce the rationale of pharmacologic inhibition of 
IGF-1/Akt/mTOR signaling for prostate cancer therapy in humans (Hay 2005), and 
suggests that ablation of survivin mRNA translation may provide an additional strategy to 
remove an anti-apoptotic mechanism potentially contributing to aggressive tumor 
behavior, in vivo. 
Materials and Methods 
Cell culture conditions 
Prostate adenocarcinoma DU145 and cervical carcinoma HeLa cells were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA).  DU145 
cells were cultured in high-glucose DMEM containing 1 mM sodium pyruvate, 10% heat 
inactivated fetal bovine serum (FBS) plus 100 U Pen-Strep antibiotic mixture, and 
maintained in a 5% CO2 incubator at 37°C, as described (Fornaro, Plescia et al. 2003).  
All cell culture reagents were purchased from Invitrogen.  IGF-1 was purchased from 
R&D System.  Rapamycin, cycloheximide and the transcriptional inhibitors, actinomycin 
D and 5,6 dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) were from Sigma.  All 
working solutions were prepared in PBS, pH 7.4.  For stimulation, 4x106 DU145 cells 
were seeded in 6-well plates in 2 ml of serum-free DMEM for 24 h, and incubated with 
increasing concentrations of IGF-1 for 12-48 h in the presence or absence of rapamycin 
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(20 nM).  When incubation reactions were prolonged to 48 h, IGF-1 and rapamycin were 
replaced daily in fresh medium.  
Modulation of protein and mRNA expression 
After IGF-1 stimulation, DU145 cells were harvested at increasing time intervals 
and solubilized in 150 µl of lysis buffer containing 20 mM Tris, pH 7.2, 0.5% sodium 
deoxycholate, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 1 mM EDTA plus 5% 
protease inhibitor cocktail tab (Roche).  Protein-normalized (50 µg) extracts were 
separated on 12% SDS polyacrylamide gels, transferred to PVDF membranes 
(Immobilon), and analyzed by immunoblotting, as described (Dohi, Beltrami et al. 2004).  
Antibodies to β-actin (1:5000, clone AC-15, Sigma), survivin (1:1000, NOVUS 
Biologicals), XIAP (1:500, BD Bioscience), or total p70S6K (1:500, Cell Signaling) were 
used with detection by chemiluminescence (Plus Reagents, Amersham Pharmacia).   
For analysis of mRNA stability, serum-deprived DU145 cells were stimulated 
with medium, IGF-1 (100 ng/ml) or 10% FBS for 6 h at 37°C.  Samples were incubated 
with 10 µM actinomycin D, or, alternatively, 50 µM DRB, harvested at 2-8 h time 
intervals, and processed for total RNA extraction (RNeasy® Mini, Qiagen, Valencia, CA).  
For analysis of protein stability, DU145 cells were incubated in serum-deprived 
conditions for 24 h, stimulated with medium, IGF-1 or 10% FBS for 18 h, followed by 
incubation with 10 µM cycloheximide.  Samples were harvested at 2-6 h time intervals, 
and protein-normalized extracts were analyzed by immunoblotting. 
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Reverse transcription and semiquantitative PCR 
Total RNA extracted from DU145 cells was reverse-transcribed (1 µg) in the 
presence of SuperScript II polymerase plus random primers (Invitrogen).  Amplification 
of survivin (27 cycles) or GAPDH (32 cycles) cDNA was carried out by semi-
quantitative PCR.  Products were separated on 1.5% agarose gels and band intensity was 
quantified using Image J software followed by GAPDH normalization. 
p70S6K transfection 
DU145 cells were transfected with WT or rapamycin-resistant p70S6K mutant 
cDNA (4 µg) using LipofectAmine 2000 (Invitrogen, 6 µl) in Opti-Mem medium (1 ml) 
(Gibco).  After 5 h, cells were incubated in serum-deprived conditions for 16 h at 37°C, 
stimulated with IGF-1 or 10% FBS for 24 h, and analyzed for changes in protein 
expression with or without rapamycin (20 nM), by immunoblotting.  For gene silencing 
experiments by small interfering RNA (siRNA), DU145 cells were transfected with 
p70S6K-directed siRNA SMARTpool (M-003616-02-0010, Dharmacon Inc.), or control 
non-targeted dsRNA oligonucleotide (VIII) using LipofectAmine 2000.  After 5 h, the 
medium was replaced with serum-free DMEM with or without IGF-1 (100 ng/ml) or 10% 
FBS.  Samples were harvested after 24 or 48 h, and analyzed by immunoblotting. 
Survivin promoter activity 
DU145 or Hela cells were transfected with survivin promoter constructs upstream 
of a luciferase reporter gene (pLuc-441 and pLuc-1430) encompassing most of the 
transcriptional requirements for survivin gene expression (Li and Altieri 1999) plus 1 µg 
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LacZ cDNA.  After transfection, cells were incubated in serum-deprived conditions for 
16 h, stimulated with IGF-1 or 10% FBS for 12 h, and analyzed for β-galactosidase-
normalized luciferase activity using a DXT 880 Multimode Detector luminometer 
(Beckman Coulter) at A405. 
Analysis of cell viability and cell cycle 
Serum-deprived DU145 cells were seeded in 96-wells plates for 24 h, and 
stimulated with medium, IGF-1 (100 ng/ml) or 10% FBS in the presence or absence of 
rapamycin (20 nM) for 24 or 48 h.  In some experiments, serum-deprived DU145 cells 
were treated with the combination of rapamycin plus taxol (25 µM) for 24 h, stimulated 
with IGF-1 or FBS, and harvested after 48 h.  After addition of 20 µl of MTT solution 
(10% of total volume, Sigma) for 4 h at 37°C, samples under the various conditions 
tested were centrifuged at 3000 rpm for 10 min, suspended in 200 µl DMSO (Sigma) for 
10 min at 22°C, and absorbance was determined at A570.  Alternatively, samples were 
analyzed for changes in survivin levels by β-actin-normalized quantitative 
immunoblotting.  In other experiments, serum-deprived DU145 cells stimulated with FBS 
or IGF-1 were stained with propidium iodide and analyzed for DNA content at 12-48 h 
time intervals by flow cytometry. 
Anchorage-independent cell growth 
Cell growth in soft agar was assayed by scoring the number of colonies formed in 
DMEM containing 0.3% agarose with a 0.5% agarose medium underlay.  R-, WT, GR35 
or GR48 (2x103) cells were seeded on 60-mm diameter plates in triplicate.  Cells were 
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fed with 1.5 ml of DMEM medium every 3 d.  Colonies larger than 100 µm were counted 
after 14 d. 
Statistical analysis 
Data were analyzed with two-sided unpaired t tests in the GraphPad software 
package for Windows (Prism version 4.0). A p value of 0.05 was considered statistically 
significant.  
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Figure 4-1.  Regulation of survivin expression by IGF-1 stimulation. 
A-C.  Serum-deprived DU-145 cells were stimulated with the indicated concentrations of 
IGF-1 (ng/ml) or 10% FBS, and analyzed after 12 h (A), 24 h (B) or 48 h (C), by 
immunoblotting.  D.  Cell cycle analysis.  Serum-deprived DU145 cells were stimulated 
with medium (None), 10% FBS or IGF-1 (100 ng/ml), and analyzed for DNA content by 
propidium iodide staining and flow cytometry at the indicated time intervals.   
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Figure 4-2.  IGF-1R transforming potential required for IGF-1-induced survivin 
expression.   
A.  Modulation of survivin expression.  MEF from IGF-1R null mice (R-) stably 
transfected to express WT, GR35 or GR48 mutant IGF-1R were stimulated with IGF-1, 
and analyzed by immunoblotting.  B.  IGF-1R tyrosine phosphorylation.  Cells were 
stimulated with IGF-1 (100 ng/ml), and lysates were immunoprecipitated with an 
antibody to IGF-1R, followed by immunoblotting.  p-Tyr, tyrosine-phosphorylated 
proteins. C.  Colony formation assay.  The indicated transfected cells were seeded in 
semisolid medium, and colonies larger than 100 µm were counted after 14 d.  Data are 
the mean±SEM of triplicates. 
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Figure 4-3.  Requirements for IGF-1 induction of survivin.  
A.  Semi-quantitative PCR.  Serum-deprived DU145 cells were stimulated with medium 
(None), IGF-1 (100 ng/ml) or 10% FBS, and analyzed for changes in survivin mRNA 
levels by GAPDH-normalized semi-quantitative PCR.  Data are the mean±SD of two 
independent experiments.  ns, not significant.  B.  Promoter analysis.  DU145 cells were 
co-transfected with survivin-luciferase promoter constructs pLuc-441 and pLuc-1430, 
stimulated with IGF-1 (100 ng/ml) or 10% FBS for 12 h, and analyzed for β-
galactosidase-normalized luciferase activity.  Data are the mean±SD of two independent 
experiments.  ns, not significant.  C.  Effect of cycloheximide on survivin levels.  Serum-
deprived DU145 cells were stimulated with IGF-1 (ng/ml) or 10% FBS, incubated with 
cycloheximide, and analyzed at the indicated time intervals by immunoblotting.  *, non 
specific. 
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Figure 4-4.  Modulation of IGF-1 induction of survivin by rapamycin. 
A, B.  Effect of rapamycin on survivin induction by IGF-1.  Serum-deprived DU145 cells 
were stimulated with the indicated concentrations of IGF-1 (ng/ml) or 10% FBS, 
maintained in the absence (A) or presence (B) of rapamycin, and analyzed by 
immunoblotting after 24 h.  *, non specific.  C, D. Modulation of survivin levels after 
transcriptional inhibition.  Serum-deprived DU145 cells were treated with the 
transcriptional inhibitors, actinomycin D (C), or DRB (D), stimulated with 10% FBS or 
IGF-1 (100 ng/ml) in the presence or absence of rapamycin, and analyzed at the indicated 
time intervals for GAPDH-normalized survivin mRNA expression by semi-quantitative 
RT-PCR.  Data are the mean±SD of two independent experiments. 
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Figure 4-5.  Requirement for p70S6K in IGF-1 modulation of survivin. 
Serum-deprived DU145 cells were transfected with WT (A) or T389E∆CT mutant (B) 
p70S6K cDNA, stimulated with IGF-1 (100 ng/ml) and analyzed in the presence or 
absence of rapamycin by immunoblotting after 24 h.  C.  siRNA silencing of p70S6K.  
Serum-deprived DU145 cells were transfected with control dsRNA oligonucleotide (left 
panel) or p70S6K-directed siRNA (right panel), treated with IGF-1 (100 ng/ml) or 10% 
FBS, and analyzed by immunoblotting after 48 h. 
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Figure 4-6.  Effect of mTOR targeting on DU145 cell viability. 
A.  Rapamycin treatment.  Serum-deprived DU145 cells were left untreated or treated 
with rapamycin, stimulated with 10% FBS or IGF-1 (100 ng/ml), and analyzed for cell 
viability by MTT after 24 h or 48 h.  *, p = 0.021-0.032.  Data are the mean±SEM of 
triplicates of a representative experiment out of at least two independent determinations.  
B. Modulation of survivin expression by taxol-rapamycin combination.  Serum-deprived 
DU145 cells were treated with the combination of taxol plus rapamycin, harvested after 
48 h and β-actin-normalized survivin levels were determined by quantitative 
immunoblotting and densitometry.  ns, not significant; ***, p=0.0004.  Data are the 
mean±SD of two independent experiments.  C.  Cell viability.  The experimental 
conditions are as in B, except that DU145 cells were analyzed for cell viability by MTT.  
ns, not significant; p=0.0046.  Data are expressed as mean±SEM of replicates of one 
experiment out of at least two independent determinations. 
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Chapter 5. Final Thoughts and Future Directions 
Profiling of cancer cells overwhelmingly demonstrates the heterogeneity of 
human cancers (Velculescu, Madden et al. 1999; Griffin, Pole et al. 2003; Lu, Getz et al. 
2005; Wood, Parsons et al. 2007), making targeting single molecules difficult in terms of 
cancer treatment.  Despite this complexity, network analysis reveals that cells rely on a 
few critical nodes which serve as hubs to redistribute biological information (Ravasz, 
Somera et al. 2002; Albert 2005).  Survivin, the cell death inhibitor and mitotic regulator, 
may act as one such hub.  This body of work solidifies survivin as a nodal protein by 
identifying two novel signaling cascades, Notch and IGF-1, which contribute to survivin 
expression and tumorigenesis.   
Notch signaling orchestrates a developmental pathway often exploited by tumors 
to regulate stem cell maintenance (van Es, van Gijn et al. 2005), modulate cell death 
(Beverly, Felsher et al. 2005; Liu, Hsiao et al. 2007), and control cell cycle progression 
(Ronchini and Capobianco 2001).  We found that Notch-1 is preferentially expressed in 
breast cancer, as compared to normal tissue, and correlates with abbreviated disease 
survival.  Both Notch-1 and survivin selectively co-segregated in patients with basal 
breast cancer, a breast cancer subtype with poor prognosis and lack of molecular targeted 
therapies.  Survivin was identified as a target of Notch-1 based on molecular studies of 
novel RBP-Jκ sites in the proximal survivin promoter (Lee, Raskett et al. 2008).  
Transcriptional activation of survivin by Notch signaling follows cell cycle periodicity of 
survivin, elevating survivin throughout the cell cycle, enhancing cell cycle kinetics and 
cell proliferation (Lee, Raskett et al. 2008).  Targeting of Notch signaling via a  γ-
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secretase inhibitor decreases survivin expression, promotes cell death, inhibits local and 
systemic tumor growth in vivo (Lee, Raskett et al. 2008).   
In our analysis of Notch-1 and survivin in breast cancer, we demonstrate that 
Notch-1 is overexpressed in breast tumors and correlated with poor prognosis (Figure 2-1 
and Figure 2-2).  However, we lack immunohistochemical data to demonstrate that 
survivin and Notch-1 are co-expressed in basal breast cancers.  This can be resolved by 
scoring Notch-1 and survivin levels in immunohistochemical staining of known basal 
breast cancers.  While the microarray analysis strengthens the co-segregation of Notch-1 
and survivin in basal breast cancers, several issues remain. The association of Notch-1 
and survivin in basal breast cancers is based on the co-segregation of Notch-1 or survivin 
with keratin-5 in ER-negative cancers (Figure 2-3).  Formally however, lack of ER is not 
completely interchangeable with basal breast cancers (Cleator, Heller et al. 2007).  
Furthermore, keratin-5 expression is one of multiple markers for basal breast cancer 
therefore using solely kertain-5 and ER status as basal markers limits the strength of the 
study.  To reinforce the Notch-1/survivin association, other Notch-1 targets can be 
assayed for co-expression with survivin.  Based on preliminary analysis of Oncomine 
data, the Notch target c-myc is selectively increased in ER-negative versus ER-positive 
breast cancers.  However, Hes-1 and Hey-1, two other Notch targets, are not 
overexpressed in ER-negative versus ER-positive breast cancers (data not shown).  
Ideally, microarray data from each study should be individually downloaded and re-
clustered to determine the association of Notch-1 and survivin with basal breast cancers. 
Despite these flaws, the strength of the existing study lies in the number of patients and 
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the collective trend demonstrating the association of Notch-1, survivin, keratin-5, and 
ER-negativity.   
The significant but modest Pearson’s correlation coefficients between Notch-
1/survivin, survivin/keratin-5, and Notch-1/keratin-5 may reflect the inaccuracies of 
microarray analysis in heterogeneous tumor populations (Figure 2-3).  Microarray 
analysis solely ascertains the predominant gene transcript levels within this cellular 
assortment.  Meanwhile, subpopulations of tumor cells with basal characteristics may be 
masked by a predominantly luminal population.  Laser microdissection or sorting of 
homogenized tumors for basal, luminal, Her2/neu, and stromal populations followed by 
microarray analysis may provide a better perspective of gene correlations.   
Microarray analysis also fails to account for tumor variability over time.  In vivo, 
a tumor population fluctuates in composition depending on external factors.  Stem-like 
cells with Notch expression and a basal breast cancer phenotype increase in population 
after stimulation with radiation or interleukin-6 (Phillips, McBride et al. 2006; Sansone, 
Storci et al. 2007).  Furthermore, treatment with trastuzumab may reorganize cellular 
signals to render the cells responsive to GSI inhibition (Osipo, Patel et al. 2008), possibly 
by encouraging a shift to a basal phenotype.  The factors that regulate plasticity of tumor 
cells have yet to be determined.  Possibly, cellular reorganization requires the 
participation of stem cell transcription factors like Oct-4, Nanog and activation of stem 
cell pathways like Notch.  Notch activation creates a pro-survival subcellular 
environment through survivin induction as well as direct changes in transcription 
patterns.   Microarray of tumors before and after any external stimuli may reveal genetic 
94 
patterns associated with drug response, and aggressive disease (Ramaswamy and Golub 
2002).   
Basal breast cancers possess embryonic stem cell like qualities (Ben-Porath, 
Thomson et al. 2008).  Likewise, survivin is associated with stem cell gene signatures 
(Pennartz, Belvindrah et al. 2004; Marconi, Dallaglio et al. 2006; Taubert, Wurl et al. 
2007) and the Wnt/β-catenin developmental pathway controls survivin expression in 
colonic progenitor cells (Kim, Plescia et al. 2003).  Survivin is also expressed in 
CD44+/CD24-/low putative breast cancer progenitor cells (Ponti, Costa et al. 2005).  
Notch-1 mediated transcription of survivin suggests a larger role of survivin as a 
candidate target in stem cell biology.  As such, the embryonic transcription factor Oct-4 
indirectly enhances survivin transcription via collaboration from other transcription 
factors like STAT3 (Guo, Mantel et al. 2008) and possibly Notch/RBP-Jκ.  In these stem 
cell populations, transcriptional activation of survivin may elevate the apoptotic 
threshold, protect the cells from environmental stress, and ensure genomic fidelity during 
mitosis.  As the isolation of stem cells and cancer stem cells improve, we will be able to 
determine the functions of survivin and Notch in stem cell populations. 
 A key aspect of our Notch-1/survivin axis is our reliance on ER status as a 
differentiating marker.  In retrospect, other characteristics, like expression of E-cadherin, 
also delineate the two groups (Table 5-2).  Expanding the analysis in additional cell lines 
or primary breast cancers may help identify the fundamental biomarkers or breast cancer 
subtypes that associates with the Notch/survivin transcription axis.  The contributions of 
ER, E-cadherin, or other biomarkers to survivin regulation also compound the issue of 
Notch driven survivin transcription.  E-cadherin expression represses survivin 
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transcription by promoting caveolin-1 sequestration of β-catenin, a transcriptional 
activator of survivin (Torres, Tapia et al. 2007).  Similarly, estrogen signaling may 
influence survivin transcription although estrogen responsive elements have yet to be 
identified in the survivin promoter.   Therefore, the effects of Notch-1 on survivin 
transcription may be augmented by existing survivin regulatory pathways in these cells.  
Most likely, cancer cells enlist multiple pathways to fine tune survivin expression.   
Notch activation drives transcription by converting RBP-Jκ from a transcriptional 
repressor to an activator.  RBP-Jκ recognizes the DNA consensus sequences GTGGGAA 
and TTCCCAC (Ling, Hsieh et al. 1994; Tun, Hamaguchi et al. 1994; Lam and Bresnick 
1998).  The survivin promoter in mouse and man lack the complete 7 bp consensus 
sequence but contain several TGGGA elements which slightly deviate from the canonical 
motif.  Despite this difference, RBP-Jκ physically associates with the survivin promoter 
during active transcription suggesting flexibility in the RBP-Jκ binding motif, at least in 
cancer cells (Figure 3-2 and Figure 3-3).  The TGGGA element also serves as a partial 
NF-κB binding element (Oswald, Liptay et al. 1998).  Coincidentally, survivin 
transcription is also regulated by NF-κB (Kawakami, Tomita et al. 2005).  Therefore, the 
cellular context in terms of transcriptional co-factors or external stimuli potentially 
functions as a switch between Notch and NF-κB driven transcription of survivin.  Given 
the overlap between RBP-Jκ and NF-κB binding elements, it is possible that Notch and 
NF-κB signals can non-discriminately activate both NF-κB and RBP-Jκ transcription 
sites.  This can be tested by assessment of survivin transcription in the context of Notch 
inactivation and NF-κB stimulation, or vice versa.  Substitution of transcription factors 
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from independent signaling pathways may be a novel component of tumor or stem cell 
plasticity. 
Our analysis of Notch targets focused selectively on survivin and other anti-
apoptotic molecules.  However, Notch signaling primarily had a functional significance 
on cell cycle modulation.  Of note, the Notch targets cyclin D1 (Ronchini and 
Capobianco 2001) and SKP2 (Sarmento, Huang et al. 2005) can accelerate G1 and S-
phase progression (Table 1-1).  Therefore, survivin may not be the sole modulator of 
Notch driven cell cycle progression.  Future experiments will be needed to determine 
whether Notch can induce cyclin D1 and SKP2 transcription in breast cancer cells.  
Likely, Notch affects multiple genes regulating multiple phases of the cell cycle 
including mitotic entry and exit.  In our experiments, G1 and S-phase progression was 
less dramatically enhanced by Notch activation, as noted by overlapping cell cycle 
profiles prior to mitosis (Figure 3-4B).  The excess of survivin at mitosis induced by 
Notch signaling possibly ensures proper alignment of chromosomes at the metaphase 
plate, formation of a functional bipolar spindle, and execution of cytokinesis (Beltrami, 
Plescia et al. 2004).   
Furthermore, the ability of Notch to rescue cells from mitotic cell death caused by 
T34A survivin attests to the specificity of Notch/survivin axis to protect mitotic 
progression (Figure 3-4D).  However, Notch activation elevates survivin protein levels at 
nearly all phases of the cell cycle suggesting that a second, non-mitotic role of Notch 
mediated survivin expression.  Notch, like survivin, is reported to protect cancer cells 
from a myriad of chemotherapeutic agents (Altieri 2003; Dohi, Beltrami et al. 2004; 
Stylianou, Clarke et al. 2006).  In addition to protecting mitotic progression, Notch 
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mediated survivin expression may promote chemotherapeutic resistance and encourage 
survival of rare cancer progenitor populations.  Exogenous survivin alone prevents cell 
death induced by GSI although GSI reduced expression of two other survival proteins, 
Bcl-2 and XIAP, suggesting the importance of survivin in the Notch survival signal 
(Figure 3-6C and Figure 3-5A).  While Notch is thought to inhibit apoptosis by 
interfering with ubiquitin mediated degradation of XIAP (Liu, Hsiao et al. 2007), we did 
not observe consistent elevation of XIAP protein levels after Notch transduction (Figure 
2-4A and Figure 3-1A).  This suggests that XIAP downregulation by GSI, at least in our 
breast cancer cells, is a result of protein instability caused by survivin depletion (Dohi, 
Okada et al. 2004).  To complete our understanding of the Notch/survivin survival 
pathway, exogenous survivin can be used to rescue Notch-1 ablation, bypassing 
criticisms of GSI off-target effects.  Possibly, the mitotic and apoptotic effects of Notch 
depletion overlap.  To address this possibility, we can treat synchronized cells with GSI 
and characterize the cell death and cell cycle profiles in an attempt to segregate the two 
functions of survivin in the Notch pathway.   
Activating Notch mutations, which bypass juxtacrine ligand stimulation, are 
prevalent in T-cell ALL (Weng, Ferrando et al. 2004).  However, such mutations have yet 
to be described in human breast cancer, although genomic analysis suggests that the 
Notch locus is a mutational hotspot (Wood, Parsons et al. 2007).  Therefore, we must 
assume that ligand association initiates the Notch pathway.  In our studies, we observed 
elevated survivin protein expression in cells stimulated by Jagged-1 ligand (data not 
shown).  Like, Notch-1, Jagged-1 has been associated with decreased overall survival and 
increased metastasis in human breast cancers (Reedijk, Odorcic et al. 2005; Reedijk, 
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Pinnaduwage et al. 2007).  Normal breast tissues express Jagged-1, -2, and Delta-like-4, 
any of which may engage the Notch receptor (Stylianou, Clarke et al. 2006).  In normal 
tissue, Notch signaling directs cell fate decisions by lateral signaling which compel 
equipotent cells to express either the Notch receptor or the ligand (Radtke and Raj 2003).  
However, tumor cells lose this regulatory component and express both receptor and 
ligand.  Translated in vivo, this implies that tumor, or stromal, cells can act as both 
activator and receiver of Notch signaling.  Furthermore, F3/contactin (Hu, Ang et al. 
2003) and excess calcium (Raya, Kawakami et al. 2004) can promiscuously activate the 
Notch receptor leading to aberrant signaling in a tumor environment.     
While our studies were limited to the Notch-1 receptor, other Notch receptors also 
activate RBP-Jκ transcription and promote breast cancer development.  In particular, 
Notch-3 may regulate cell proliferation in ErbB2 negative cells (Yamaguchi, Oyama et 
al. 2008).  Intriguingly, overexpression of Notch-2 is correlated with low grade cancers 
and improved survival (van de Vijver, He et al. 2002).   Recruitment of different 
transcriptional co-factors may explain the contradictory effects of Notch-2.  Finally, 
Notch-4 inhibition with a Notch-4 specific antibody reduces formation of mammospheres 
derived from primary ductal carcinoma in situ (Farnie, Clarke et al. 2007).   
Characterizing the tumorigenic potential of each Notch receptor will aid in the 
development of receptor specific therapeutics, potentially with reduced side effects. 
In the context of breast cancers, Notch targeting is hotly pursued as a cancer 
therapeutic.  GSI treatment in our xenograft basal breast cancer model reduces local and 
systemic disease (Figure 3-7).  Notch signaling in certain cell types can induce epithelial 
mesenchymal transition and metastasis (Timmerman, Grego-Bessa et al. 2004; Leong, 
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Niessen et al. 2007) while survivin expression is correlated to metastatic disease (van 't 
Veer, Dai et al. 2002; Paik, Shak et al. 2004).  Further work will be needed to 
characterize the molecular contributions of survivin to invasion and metastasis.  While 
GSI treatment inhibited tumor growth, a limitation in our studies is the absence of in vivo 
tracking of Notch inhibition.  Attempts to stain tumor sections with survivin were 
unsuccessful (data not shown) but alternative methods may be used to monitor Notch 
activity.  Whole spleens can be assayed for Notch activity in T-cells (Palaga, Miele et al. 
2003).  Alternatively, tumors can be resected at earlier timepoints to facilitate 
immunohistochemical staining for Notch, survivin, or caspase activity.   
Notch inhibition with GSI carries a concern of severe toxicities.  GSI treated mice 
lose transient amplifying cells in the intestine leading to goblet cell metaplasia within the 
colonic crypt (Milano, McKay et al. 2004; Wong, Manfra et al. 2004).  Furthermore, 
Notch signaling is a critical component of T-cell development (Robey, Chang et al. 1996) 
and peripheral T-cell function (Palaga, Miele et al. 2003).  While GSI toxicities may be a 
result of the mouse background, the type of GSI, and the purity of the GSI, the potential 
toxicities are concerning and warrant scrutinization in human studies.  However, GSI 
treatment in our mice show limited toxicities with effective tumor inhibition suggesting 
that GSI can be safety administered (Figure 3-7).  GSI trials in human breast cancer 
(NCT00106145 and NCT00645333) encourages optimism as side effects, while severe, are 
likely to be manageable with intermittent dosing (Krop, Kosh et al. 2006).   
In contrast to the Notch-survivin transcriptional signaling axis, analysis of IGF-1 
signaling in prostate cancer uncovered a post-transcriptional regulatory component of 
survivin expression.  Early state prostate cancer is dependent on androgens for growth 
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and survival, therefore, the main treatment options center on androgen removal by 
surgery, radiation or hormone ablation.  As the disease progresses, the prostate cancer 
cells develop insensitivity to androgen signaling and the cancer recurs.  IGF-1 signaling 
increasing survivin may contribute to the development of androgen independence by 
elevating the apoptotic threshold.  In prostate cancer cells, IGF-1 stimulation increases 
expression of survivin by stabilization and translation of survivin mRNA (Vaira, Lee et 
al. 2007).  Interfering with signals downstream of IGF-1 with IGF-1R mutants, 
rapamycin or gene silencing of p70S6K abrogated IGF-1-survivin signaling and 
sensitized prostate cancer cells to traditional cytotoxics (Vaira, Lee et al. 2007).  This 
translational mechanism of survivin expression is independent of transcriptional 
regulation or protein stabilization of survivin and unaffected by cell cycle progression.  
The rapid tuning of survivin levels allows cells to respond instantaneously to fluctuations 
in the tumor microenvironment.  Persistent activation of IGF-1/survivin signaling 
provides the tumor with an increased threshold to apoptotic induction, promoting the 
development of anti-cancer therapy resistance and heralding the onset of clinically 
aggressive disease (Oh, Jin et al. 2008).  
Although our study focused on IGF-1R homodimerization, the IGF-1R receptor 
can dimerize with several other receptors.  Heterodimerization of IGF-1R with EGFR 
(Morgillo, Woo et al. 2006), ErbB2 (Nahta, Yuan et al. 2005), and the insulin receptor 
(Pandini, Frasca et al. 2002) is reported to contribute to drug resistance.  IGF-1R and 
ErbB2 heterodimerization in breast cancers cells results in resistance to trastuzumab 
(Nahta, Yuan et al. 2005).  In non-small cell lung cancer, the heterodimerization of IGF-
1R to EGFR promotes drug resistance to erlotinib by stimulating mTOR dependent 
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protein synthesis of survivin (Morgillo, Woo et al. 2006).  Heterodimerization of IGF-1R 
in prostate cancer may trigger accumulation of survivin protein in response to anti-
hormonal therapies.  This may be a mechanism for prostate cancer cells to evolve toward 
androgen independence.  Furthermore, heterodimerization may confer tissue or cell type 
specificity to the IGF-1R/survivin pathway.   
The IGF-1 signal transduction pathway can activate many pathways including the 
MAP kinase pathway, the ERK pathway, and the PI3K pathway (Craparo, O'Neill et al. 
1995; Ryan and Goss 2008).  In acute myeloid leukemia, both the ERK and PI3K 
pathway induces survivin mRNA and protein (Carter, Milella et al. 2001).  In prostate 
cancer, IGF-1 predominantly regulates survivin translation through downstream signaling 
via PI3K.  However, given the importance of the MAPK and ERK pathways in 
tumorigenesis, they may be explored for a contribution to survivin regulation in the 
context of IGF-1 signaling.   
The current study utilizes transcriptional and protein synthesis inhibitors to track 
mRNA translation (Figure 4-4).  While these methods are sufficient, more rigorous 
procedures can complement the existing work.  Northern blotting of survivin mRNA 
associated with polyribosomes can reveal translation patterns of survivin splice variants 
under conditions of IGF-1 stimulation (Li, Bor et al. 2006).  Survivin splice variants have 
a conserved N-terminal suggesting that the same promoter elements regulate their protein 
expression (Sampath and Pelus 2007).  Therefore, post-transcriptional mechanisms like 
IGF-1 regulation of mRNA translation may regulate expression of survivin splice 
variants.  Preferential translation of splice variant survivin-∆Ex3 may provide enhanced 
apoptotic threshold since the splice variant can interact with Bcl-2 to inhibit caspase 3 
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(Wang, Sharp et al. 2002).  Likewise, regulation of survivin translation may control 
intracellular survivin availability by influencing subcellular localization (Dohi, Beltrami 
et al. 2004), phosphorylation (Dohi, Xia et al. 2007) or ubiquitination (Vong, Cao et al. 
2005) which can be tracked with 35S-methionine.  Pulse-chase labeling with 35S-
methionine will also provide a precise analysis of protein stability.   
The IGF-1 translational control of survivin was inhibited by rapamycin which is 
primarily a mTORC1 inhibitor.  However, evidence suggests that prolonged treatment 
with rapamycin could also inhibit mTORC2 activity (Sarbassov, Ali et al. 2006).  
Immunoblotting IGF-1 stimulated or rapaymcin inhibited cells for phosphorylated 
p70S6K1 can identify mTORC1 activity.  To monitor mTORC2 activity, cell lysates can 
be analyzed for Akt activity although this may be a cell type dependent effect (Sarbassov, 
Ali et al. 2006).  Alternatively, we may immunoprecipitate the mTOR complex to 
determine the raptor/rictor ratio to assess mTORC1 or mTORC2 activity.   
The two pathways highlight the tissue specificity of survivin regulators.  IGF-1 
regulates survivin translation in prostate cancer cells (Vaira, Lee et al. 2007) and non-
small cell lung cancer (Morgillo, Woo et al. 2006) but not in MCF-7 or MDA-MB-231 
breast cancer cells (data not shown).  This may reflect the differences in the 
microenvironments of each cancer tissue, the dominance of signaling pathways in 
particular cancer types, or the variability of genetic landscapes in different tumors.  Our 
analysis of GSI sensitivity across different cell types suggests that other tumor types may 
also rely on Notch/survivin signaling (Supplemental Figure 3-10).  Comparatively, PC3 
prostate cancer cells, H1975 non-small cell lung cancer cells, and A431 squamous skin 
carcinoma cells are more sensitive to GSI than DU145 prostate carcinoma cells, H460 
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large cell lung cancer cells, HCT-116 colon carcinoma cells, HeLa cervical carcinoma 
cells, or U87MG glioblastoma cells (Supplemental Figure 3-10).  However, a brief 
analysis of p53 status, EGFR expression, ER/PR/Her2 expression, and IGF-1R status 
does not reveal any pattern as to why some cell respond to IGF-1 while others respond to 
Notch (Table 5-2).  A more comprehensive genomic comparison may reveal patterns 
associated with Notch or IGF-1 mediated survivin regulation.   
Even so, further work will be required to determine why survivin regulation 
shows tissue specificity.  One explanation is that changes in the transcriptional 
environment may affect survivin regulatory pathways.  The tumor suppressor p53, which 
is frequently lost or mutated in tumor progression, represses the survivin promoter by 
recruiting chromatin deacetylation complexes (Mirza, McGuirk et al. 2002), and via 
direct inhibition of the survivin promoter (Hoffman, Biade et al. 2002).  Similarly, 
differences in promoter associated transcription factors, chromatin structure, and DNA 
methylation patterns may help explain tissue specificity.  In the future, a detailed 
identification of transcription factors, histones, and chromatin modifications associated 
with the survivin promoter can be determined using ChIP on chip technology.   
Furthermore, Notch mediated expression of survivin was selectively activated in 
tumor cells compared to normal cell lines (Figure 3-1B and C).  The IGF-1-survivin 
upregulation was not tested on normal cell types, but may follow a similar paradigm.  
This suggests that survivin regulatory pathways are different in normal versus tumor 
tissues.  Multiple aberrant pathways may drive survivin expression in tumor cells because 
tumors rely on the dual nature of survivin to bypass mitotic regulation and overcome 
apoptotic stress (Altieri 2003).  Fluctuations of survivin levels inflicted by survivin 
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antagonists may significant impair tumor viability.  Conversely, normal tissues are less 
affected by changes in survivin levels because a minimal level of survivin is needed 
during mitotic progression.  Since the majority of work analyzing the functions of 
survivin in mitotic regulation and apoptotic inhibition was conducted in tumor cells, 
characterization of survivin in normal tissue may reveal differences that can be 
manipulated to selectively target survivin in tumor tissue.   
Our studies thus far suggest that cancers are “addicted” (Weinstein and Joe 2006) 
to survivin for survival.  Basal breast cancers are “addicted” to the Notch/survivin 
signaling axis.  The basal breast cancer cell types were more sensitive to GSI treatment 
compared to luminal breast cancer cell types and normal cell types (Figure 3-5C).  In 
these cells, depletion of Notch resulting in reduced survivin becomes a fatal event.  
Androgen independent prostate cancers are possibly “addicted” to the survival 
environment created by IGF-1 modulation of survivin.  This suggests that survivin 
regulation may be coupled to other “addictive” pathways depending on the tumor type.  
These partner pathways may include EGFR in non-small cell lung cancer and Wnt/β-
catenin in colorectal cancer (Kim, Plescia et al. 2003).  Identification of survivin partner 
pathways will reveal key “oncogenic addiction” pathways which can be targeted to 
propel us toward tailored cancer therapy. While these concepts require further 
characterization, survivin directed anti-sense molecules, dominant negative viruses, and 
transcriptional repressors are all in various phases of clinical development (Table 5-1) 
(Altieri 2008).  Preliminary results are promising with phase I clinical trial data 
demonstrating tumor regression with minimal side effects (Tolcher, Antonia et al. 2006).   
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Existing data overwhelmingly place survivin in the center of a tumor network.  
Many regulators, protein interactors, or upstream signals of survivin are tumor 
suppressors or oncogenes exploited by tumor cells (Figure 1-1)(Altieri 2008).  This work 
identifies two additional pathways that regulate survivin in tumorigenesis.  IGF-1 
signaling promotes translation of survivin mRNA while the Notch developmental 
pathway transcriptionally controls survivin expression.  The integration of survivin into 
these networks strengthens the argument that survivin functions as a nodal protein.  This 
nodal property of survivin is the rationale for developing survivin antagonists that may 
bypass tumor heterogeneity by debilitating multiple tumor specific pathways. 
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Table 5-1.  Survivin antagonists in clinical development.   
(Altieri 2008) 
Therapy Function Stage 
Molecular Antagonists  
Survivin RNAi  Survivin shRNA cocktail Planned 
preclinical 
Survivin Ribozyme  Hammerhead ribozyme targeting exon 1 
of survivin   
Planned 
preclinical  
LY2181308  Survivin anti-sense drug Phase II  
Gene Therapy  
Dominant negative 
mutants C84A, 
T34A  
Interfering mutants of survivin  Preclinical  
Survivin gene 
promoter targeting  
Survivin gene promoter driving cytotoxic 
gene expression  
Planned 
preclinical 
Immune Therapy  
Survivin Peptide 
Vaccine  
immunotherapy  Phase I/II  
Autologous CTL 
pulsed with survivin 
primed dendritic 
cells  
Vaccine primed autologous T cells 
Survivin Sur1M2 peptide vaccine  
Phase I/II  
Small Molecule Inhibitors  
YM155  Inhibit survivin mRNA transcription Phase II  
EM1421  Inhibit Sp1 regulated survivin expression, 
Tetra-O-methylnordihydro-guaiaretic acid  
Phase I  
Flavopirodol  Inhibit cdc2 phosphorylation of survivin Phase I/II  
Shepherdin  Survivin derived antagonists Preclinical  
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